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CHAPTER 1. ANTASCOMICIN B AND EPOXYQUINOLS
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1.1 Introduction

1.1.1

Antascomicin B

FK-520 (Ascomycin, Immunomycin), rapamycin (Rapamune®, sirolimus), and FK-506
(Prograf®, tacrolimus, fujimycin) have powerful immunosuppressive properties (Figure 1).1, 2, 3
These molecules are not directly immunosuppressive, but rather they form a complex with the
intracellular binding protein FKBP12 (FK-506 binding protein, macrophilin), and it is this complex
that is responsible for the immunosuppressive effects. Both FK-506/FK-520 and rapamycin bind to
FKBP12 in a similar fashion, but they differ in non-FKBP12 binding (effector) domains which
results in different modes of immunosuppressive action. The open effector domain of both the FK506/FKBP12 and FK-520/FKBP12 complexes binds calcineurin,1, 4-6 forming a ternary complex that
prevents the transcription of genes responsible for coding interleukin-2 (IL-2) and its receptor. The
target of the effector domain of the rapamycin/FKBP12 complex is mTOR, a protein responsible for
controlling cell growth and proliferation. This ternary complex blocks entry of lymphocytes into
the cell, thus inhibiting cell proliferation.3, 6, 7
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In 1996, a group at Sandoz Pharma conducted a study to identify strains of bacteria that
could produce macrophilin-binding metabolites.8 Of the approximately 12,000 strains that were
tested, only one produced compounds that could bind macrophilin. The producing strain was a soil
bacterium of the genus Micromonospora collected from soil samples from China. The active
compounds of interest are known as antascomicin A, B, C, D, and E (Figure 2).
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The antascomicins bind FKBP12 to the same degree as rapamycin and FK506, yet show no
immunosuppressive activity. They do not inhibit proliferation of T-cells and, moreover, they
actually antagonize the inhibitory effects of rapamycin and FK506.9
In 1992, Snyder discovered that FKBP12 exists in much higher concentrations in the brain
and nervous system than the immune system.10 This was the first indication that immunophilins
such as FKBP12 might play a neural role. Snyder later showed that the FKBP12/rapamycin and
FKBP12/FK506 complexes did in fact display neurotrophic activity in mouse models.11 However,
the immunosuppressive characteristics of these complexes limited their usefulness in the treatment
of damaged nerves. This encouraged researchers to seek out non-immunosuppressive FKBP12
binding ligands.12
The antascomicins and other small molecules that bind FKBP12, but do not cause
immunosuppression, lack the effector domain required for calcineurin or mTOR.13 FKBP12 binding
complexes that lack an effector domain were shown to have potent neuroprotective and
neuroregenerative properties in mouse models of Parkinson’s disease.12 The antascomicins are
among the few naturally occurring molecules that have been identified that bind FKBP12 but do not
show immunosuppressive activities. This leads us to believe that the antascomicins could be
potential chemotherapeutics in the treatment of the devastating, neurodegenerative Parkinson’s
disease.12, 13
Biologically, antascomicin B is an interesting target because, of all the antascomicins, it
showed the greatest affinity towards binding with FKBP12, is mobile across the blood brain
barrier,10 and does not show any immunosuppressive effects.12
In 2005 the total synthesis of antascomicin B was reported by Stephen Ley’s group at
Cambridge University.14 The C18-C34 fragment of antascomicin A has been synthesized by Fuwa et
al.15 Chakraborty et al. have published syntheses of the C1-C21 and C22-C34 fragments of
antascomicin A.16, 17
4

1.1.2 The C34-C29 Unit of Antascomicin B

Our group has been engaged in the total synthesis of antascomicin B for several years.18-20
Retrosynthetically, we envision antascomicin B being the product of late convergence of the C20-C1
fragment and the C34-C21 fragment (Figure 3). In this document, we will report the efforts toward
the enantioselective synthesis of the C34-C21 fragment. When looking at the C34-C21 region of
antascomicin B, a good starting point presented itself as the terminal trihydroxycyclohexyl C29-C34
moiety.

The C29-C34 cyclitol moiety thus provided us with our first synthetic challenge. In order to
complete the eventual total synthesis of antascomicin B, we first had to develop an asymmetric
method to produce large quantities of the six carbon fragment. A comparatively efficient, albeitn
racemic, five-step synthesis of trihydroxyenone 2.1 has previously been reported,21 In which
epoxyquinol 2.2 was hydrolyzed to anti-anti-trihydroxyenone 2.1 (Scheme 2). Therefore, the first
challenge was obtaining large quantities of enantiopure epoxyquinol 2.2.
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1.1.3 Epoxyquinols

Epoxyquinol 2.2 (Figure 4) is an important intermediate for a number of reasons. It is in
itself a very synthetically useful molecule: all 6 carbons possess unique reactivity. This imbues
epoxyquinol 2.2 with potentially broad applications in synthesis. The synthesis of the target has
been reported previously,22 but prior to our work,20 no efficient asymmetric approach to transepoxyquinol 2.2 had been reported.
The epoxyquinol moiety is the focus of this chapter and two primary topics are covered:
asymmetric synthetic strategies toward trans-epoxyquinols and the occurrence of transepoxyquinols in nature.
The first section details syntheses of the desired enantiomer of the six carbon core of either
epoxyquinol 2.2 or trihydroxyenone 2.1. These are syntheses of either 2.2 or 2.1 or syntheses of
6

derivatives differentiated only by protecting groups. The following section will cover
representative technologies developed toward accessing derivatives or enantiomers of the desired
trans-epoxyquinol. We will focus attention on elements of the syntheses concerned with how the
epoxyquinol was accessed. The final section will cover trans-epoxyquinoid natural products. If a
relevant asymmetric synthesis has not been covered before the final section, it will be discussed
therein.
Several research groups have developed unique methodologies for accessing the
epoxyquinol, and there is a general trend for groups to employ their respective technologies toward
the syntheses of multiple natural products. That being said, each methodology will be discussed
only once using a representative example. If a previously reviewed methodology is applied to the
synthesis of a natural product, it will only be mentioned briefly in the text.

1.2 Synthetic Strategies Toward the Epoxyquinol or Trihydroxycyclohexenone Core

1.2.1 Paulsen
Paulsen reported the platinum catalyzed oxidation of several carbohydrates and cyclitols
and found that (+)-conduritol-F would oxidize to trihydroxy cyclohexenone 3.1 (Scheme 3). He
reported that only the axial alcohol was oxidized while equatorial alcohols were left intact.23 (+)Conduritol F is a naturally occurring substance and was isolated in 1962 from the Oxeye Daisy
Chrysanthemum leucanrhemum, albeit in small quantities.24 The synthesis of (+)-conduritol F was
reported most recently in five steps from commercially available (+)-proto-quercitol, which is $202
for 100 mg from TCI America (Scheme 2).25, 26 The high cost of the starting material, combined with
the poor yield of the final transformation, make this an impractical approach to the
trihydroxycyclohexenone.
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1.2.2 Winterfeldt

In 1993, Winterfeldt et al. described the synthesis of the epoxyquinol via Diels-Alder
reaction between p-benzoquinone and chiral diene 4.1, followed by epoxidation to 4.3, which was
regio- and diastereoselectively reduced to alcohol 4.4. Retro Diels-Alder under vacuum furnished
the epoxyquinol in high yield (Scheme 4). Diene 4.1 was obtained from Hajos-Wiechert ketone in 4
steps and 29% overall yield. The final retro Diels-Alder was reported on a 162 mg scale and was
executed in a kugelrohr apparatus at high temperatures.27 The major drawback to this strategy is
the extra effort required to synthesize chiral diene 4.1.
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1.2.3 Ogasawara

In a report of the total synthesis of the natural product (-)-tricholomenyn A in 1996,
Ogasawara and Kamikubo reported the preparation of enantiopure epoxyquinol silylether 5.8 as an
intermediate (Scheme 5).28 This route is one of the most cited in the literature and the enzymatic
desymmetrization approach has been used to access myriad chemical targets.29 Most recently the
methodology was applied in the syntheses of several polyoxygenated cyclohexanoids.30 However,
this strategy has several drawbacks. First, even though the Luche reduction has been reported on a
50 gram scale, 31 in our hands, reduction of Diels-Alder adduct 5.1 proved unscalable beyond a 3
gram threshold. Second, the desymmetrization step requires a one equivalent by weight loading of
the immobilized enzyme PS-D; the enzyme is quite expensive at around $9 per gram from SigmaAldrich. Finally, the synthesis suffers from operational inefficiency in general, involving
cumbersome protection-deprotection and redox sequences.

9

1.2.4 Shair

Most recently, Shair et al. developed a ten-step procedure to produce differentially
protected trihydroxycyclohexenone 6.4 starting from methyl-α-D-glucopyranoside (Scheme 6).32
They used a literature procedure to produce benzylidene acetal 6.1 in 4 steps from methyl-α-Dglucopyranoside.33 Acidic hydrolysis of the acetal followed by conversion of the primary alcohol to
an iodide and silylation of the secondary alcohol afforded iodide 6.2 in good yield. Reductive
fragmentation of iodide 6.2 by sonication over zinc powder produced an aldehyde, which was
converted to allyl alcohol 6.3 after treatment with vinyl Grignard. Ring closing metathesis via first
generation Grubbs catalyst formed the six-membered ring which was oxidized to differentially
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protected trihydroxycyclohexenone 6.4 via Parikh-Doering oxidation for a total of ten steps and
26% overall yield.

1.3 Syntheses of Epoxyquinol Derivatives
Accessing the core structure of the epoxyquinol has been achieved by several groups by
several different methodologies. Those methodologies will be covered in the following section.

1.3.1 Banwell: (-)- Bromoxone

In 2009, Banwell et al. published a report wherein (-)-bromoxone (7.6) was obtained in
enantiopure form from arene cis-arenediol halogen 7.1 (Scheme 7).34 Bromodiol 7.1 is the product
of dihydroxylation of bromobenzene mediated by toluene dioxygenase35 and can be purchased
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from Sigma-Aldrich for $291 for 5 g. Bromodiol 7.1 was converted to bromohydrin 7.2 which was
selectively converted to epoxide 7.3 upon treatment with sodium methoxide. Mitsunobu reaction
to the alcohol with chloroacetic acid produced ester 7.4, thus establishing the trans-hydroxy
relationship to the epoxide. Oxidation of the remaining alcohol followed by deprotection gave the
natural product (-)-bromoxone (7.6) in 5 steps and 20% overall yield from bromodiol 7.1.

1.3.2 Kitahara: (+)- Epiepoformin

Following a procedure developed in 1985,36 Kitahara’s group was able to reduce βketoester 8.1 into the corresponding β-hydroxyester 8.2 with high enantioselectivity using baker’s
yeast (Scheme 8).37 Hydrolysis of the ester followed by acylation of the secondary alcohol led to
acid 8.3. Oxidative decarboxylation of acid 8.3 delivered a diastereomeric mixture of iodides 8.4.
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The scrambling of this stereocenter was inconsequential, since subsequent dehydriodination
eventually removed it. Hydrolysis of the acetate followed by reprotection as the silylether afforded
8.6. Deacetalization to enone 8.6 was followed by stereoselective epoxidation to 8.7, which was
then converted to phenylselenide 8.8 in two steps. A methyl group was then introduced via the
enolate of 8.8 to give methyl selenide 8.9. Subsequent oxidative elimination of PhHSe=O and
deprotection of trans-hydroxy group yielded the natural product (+)-epiepoformin 8.11.

1.3.3 Okamura: (+)-Epiepoformin

Okamura’s group reported the synthesis of (+)-epiepoformin via stoichiometric asymmetric
Diels-Alder approach (Scheme 9).38 Activation of diene 9.1 with the chiral base cinchonidine
initiated a Diels-Alder reaction with chiral dienophile 9.2. The reaction provided Diels-Alder
adduct 9.3 as a single diastereomer. Methanolysis followed by silylation of the resultant secondary
alcohol gave diester cyclohexene 9.4. Both esters were reduced to the 1, 2-diol which underwent
13

oxidative cleavage to give cyclohexenone 9.5. The primary alcohol was then converted to the
tosylate, which underwent subsequent elimination. The resultant exocyclic double bond was then
isomerized to the endocyclic alkene via activated palladium on carbon. Conversion of alcohol 9.5 to
the tosylate and hydrogenolysis afforded (+)-epiepoformin (9.6) after desilyation.

1.3.4 Ryu: Precursor to (+)-Bromoxone, (+)-Epiepoxydon, and (+)-Epiepoformin

Ryu et al. reported syntheses of (+)-bromoxone, (+)-epiepoxydon, and (+)-epiepoformin
using a catalytic asymmetric Diels-Alder reaction (Scheme 10).39 The silyl ether of epoxyquinol
10.7 was an intermediate in the syntheses of all three products. , In the presence of a chiral
catalyst, 2-iodo-1,4-quinone monoketal 10.1, which is obtained in two steps from 2-iodo phenol,
underwent an enantioselective Diels-Alder reaction with cyclopentadiene. The iodine was then
reduced from the Diels-Alder adduct to give enone 10.3, which underwent Luche reduction to give
14

alcohol 10.4. Deprotection to ketone 10.5 created the opportunity to protect the secondary alcohol
as silyl ether 10.6. Retro Diels-Alder furnished the silyl ether of epoxyquinol 10.7.

1.3.5. Lee: (-)-Harveynone

Lee et al. reported the syntheses of the natural products (-)-harveynone, and (-)tricholomenyn A using an asymmetric epoxidation and relay metathesis (Scheme 11).40 Synthesis
began with the Sharpless asymmetric epoxidation of diol 11.1, followed by oxidation to afford
epoxy aldehyde 11.2 as a single enantiomer. Addition of acetylide of 11.3 provided a separable 1:2
mixture of diastereomers in favor of the undesired epimer. The desired isomer 11.4 underwent a
series of functional group manipulations to yield aldehyde 11.5, while the undesired ent-11.4 was
epimerized to rejoin the synthetic pipeline. Towards the synthesis of harveynone, the aldehyde
11.5 was exposed to triethylsilyl-1, 3-pentadiyne and a catalytic amount of fluoride to provide 11.7.
Upon treatment with second-generation Grubb’s catalyst, a relay metathesis occurred to give
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dienyne 11.8. Further functional group manipulation afforded the natural product (-)-harveynone
11.9.

1.4 Epoxyquinoid Natural Products

1.4.1 Introduction
The epoxyquinol core appears in a number of natural products, of which the vast majority
are fungal metabolites. A rare exception is cetoniacytone A (Figure 13), which is a bacterial
metabolite.41 The current section identifies natural products bearing trans-epoxyquinol
functionality and discusses biological activity as well as relevant synthetic strategies. Any student
interested in epoxyquinols should start their investigation with Marco-Contelles’ excellent review.42
It is a thorough examination of the field up to 2004. It covers natural occurrence, biological
16

significance, and synthetic efforts toward the epoxyquinoids. That being said, it bears reviewing
and updating so as to give the reader of this document a sound background in the subject.

1.4.2 Epiepoformin

(+)-Epiepoformin (Figure 5) was first isolated from the culture broth of an unidentified soil
fungus taken from the rhizosphere of a potted asparagus plant.43 The fungus was also found on
infected leaves of a crape myrtle tree.44 (+)-Epiepoformin exhibits strong phytotoxicity and
cytotoxicity. Media containing the compound inhibited germination of lettuce seeds significantly. It
also provided complete control of redroot pigweed and significant control of white mustard when
applied at 4.4 kg/ha.44
(±)-Epiepoformin was first synthesized by Ichihara via a retro-Diels Alder approach.45 The
synthesis helped determine the relative configuration of epiepoformin. Ogasawara has accessed
both natural (+)-epiepoformin and unnatural (-)-epiepoformin via enzymatic desymmetrization of
a meso-diol.46 Okamura accessed (+)-epiepoformin using a stoichiometric asymmetric Diels-Alder
approach.47
Maycock developed a route to (+)-epiepoformin using quinic acid as starting material
(Scheme 12).48, 49 β-Silylether ketone 12.1 was accessed in 5 steps and 73% overall yield from (-)quinic acid ($52 for 25 g, Sigma-Aldrich). Base-induced elimination of 12.1 proceeded with an
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unintended silyl migration to give a 1:1 mixture of isomeric enones 12.3 and 12.4, which were
epoxidized as a mixture to give epoxides 12.4 and 12.5. Treatment of epoxides 12.4 and 12.5
with Ac2O, Hünig’s Base, and DMAP gave the desired elimination product 12.6 as well as acylated
12.4 which were separated by column chromatography. Installation of the methyl group followed
by deprotection, furnished (+)-epiepoformin in 11 steps with 20% overall yield.

A more recent approach comes from Figuerdo and takes advantage of a thiophenyl directing
group and enzymatic resolution to establish the correct stereochemistry (Scheme 13).50 First,
monoacetal protected p-benzoquinone 13.1 was treated with thiophenol in the presence of LiOH
gave a mixture of products, from which monoaddition product 13.2 was separated. Reduction of
enone 13.2 with NaBH4 yielded only cis-alcohol, which led to a mixture of enantiomers 13.3 which
were separated via enzymatic acylation to yield the desired acetate 13.4. Deacylation, followed by
reprotection as the silylether led to hydrolysis of acetal to form ketone 13.5. The thiophenyl
stereocenter was scrambled during this step but this proved inconsequential. Methylation via the
enolate of 13.5 gave a mixture of epimers 13.6. Employment of a bulky peroxide in the epoxidation
step led solely to the trans-epoxide 13.7. Oxidation of the thiophenyl group led to a mixture of both
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endocyclic and exocyclic alkenes 13.8 and 13.9. Fortunately, conditions designed to cleave the
silylether also isomerized the exocyclic alkene to the natural product (+)-epiepoformin in 10 steps
and 10% overall yield from 13.1.

Schapiro has recently published a synthesis of unnatural (-)-epiepoformin (Scheme 14).51
The synthesis commenced with whole cell oxidation of toluene to afford a dihydrodiol which was
converted to acetonide 14.1. Selective iodohydroxylation followed by hydrolysis of the acetonide
gave iododiol 14.2. Oxidation and ring closure yielded epoxide 14.3. Deacylation yielded the
natural product (-)-epoformin. Mitsunobu inversion over (-)-epoformin gave p-nitrobenzoate 14.4,
which was hydrolyzed to (-)-epiepoformin.

19

(+)-Epiepoformin was synthesized in Carreno’s lab using a chiral sulfoxide auxiliary
addition to quinone monoketal 15.1 (Scheme 15).52 Diastereoselective conjugate addition of a
methyl group followed by α-bromination gave 15.3. Elimination of HBr gave dienone 15.4.
Regioselective epoxidation led to 15.5 which was reduced to epoxy alcohol 15.6. Base promoted
cleavage of sulfoxide 15.6 furnished (+)-epiepoformin for a 9 step synthesis from 15.1 in 9%
overall yield.

20

1.4.3 Epiepoxydon

Epiepoxydon (Figure 6) was first reported in the literature as a synthetic product.53 Later, it
was isolated from the fermentation broth of a fungus found on diseased crape myrtle leaves.44 It
has also been isolated as an intermediate in the patulin pathway in Penicillium urticae and in all
instances it has been characterized as a phytotoxin.54, 55 It was reported to have significant
cytotoxic activity in the brine shrimp assay and also towards human cancer cell lines. It exhibited
an LC50 of 3.6 μg/ml against human breast cancer cells.56, 57
Epiepoxydon has been synthesized a number of times: the first effort was from Ichihara’s
group who reported a racemic synthesis of the target via a retro-Diels Alder strategy.53, 58, 59
Ogasawara modified the retro-Diels Alder approach to make it asymmetric. 60 Taylor reported a
synthesis of (±)-epiepoxydon from epoxyquinol 16.1 using a Baylis-Hillman reaction (Scheme 16).61
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Mehta has reported the enantioselective synthesis of (+)-epiepoxydon via enzymatic
desymmetrization of the corresponding meso-diol.62 Kitahara reported the synthesis of (+)epiepoxydon using baker’s yeast to induce asymmetry.63 Ryu’s group synthesized (+)-epiepoxydon
through a catalytic asymmetric Diels-Alder approach.64 Banwell reported the synthesis of (+)epiepoxydon where absolute configuration was achieved by dihydroxylation of bromobenzene
mediated by toluene dioxygenase.65

1.4.4 Harveynone and Tricholomenyn A

(+)-Harveynone (Figure 7) also know as “PT-toxin” is produced by the tea gray blight
fungus Pestalotiopsis theae and is a known phytotoxin.66 (-)-Harveynone was isolated from the
fungus Curvularia harveyi; it is also phytoxic and has shown anti-tumor activity.67 Tricholomenyn A
was isolated from the fungus Tricholoma acerbum and is an antimitotic.68
(+)-Harveynone and (-)-tricholomenyn A were both synthesized by Ogasawara using a
Stille-coupling reaction betweenan enzymatically derived epoxyquinol and the appropriate
acteylenic fragment. Their work determined the absolute configuration of (+)-harveynone.28, 69
Around the same time, Taylor reported the synthesis of (±)-harveynone and (±)-tricholomenyn A in
a fashion similar to Ogasawara’s.70 Maycock reported the synthesis of (+)-harveynone from (-)quinic acid.49 Taylor reported a synthesis of the (-) form of both natural products that used
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immobilized lipase to effect enzymatic resolution of diacetate 17.1 to enantiopure diol 17.2
(Scheme 17).70 After functional group manipulation to achieve the epoxyquinol core 17.4, they
were able to furnish both natural products using a Sonogashira coupling with the appropriate
alkyne. The syntheses were carried out in 11 total steps with 3% yield for (-)-harveynone and 4%
yield for (-)-tricholomenyn A. The epoxyquinol core was built in 9 steps with 4% overall yield.

Negishi reported a similar protocol wherein Pd-catalyzed cross-coupling with the
appropriate alkynylzinc precursor afforded racemic harveynone and tricholomenyn A.71 Total
syntheses of (-)-harveynone and (-)-tricoholomenyn A have been reported by Banwell72, 73 and
Lee.74 Taylor also recently reported the synthesis of (-)-harveynone via halogen-substituted parabenzoquinone monoketal.75 Carreno reported development of a very late stage intermediate of (+)harveynone via a chiral sulfoxide auxiliary; unfortunately they were unable to convert it to the
natural product.52
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1.4.5 Panepoxydon, Isopanepoxydon, and Cycloepoxydon

Panepoxydon (Figure 8) was isolated from the culture broth of the fungus Lentinus crinitus
and the basidiomycete conchatus; it was found to inhibit the NF-κB- activated expression of
secreted alkaline phosphatase (SEAP) at an IC50 value of 5 μg/ml.76,77 Panepoxydon has been shown
to have cytotoxicity values ranging from IC50 0.9-1.9 μg/ml against various cell lines and it showed
activity against the malarial parasite P. falciparum with an IC50 of 3.4 μg/ml.78 It also showed
significant inhibitory activity on trypanthione reductase (TR) in the parasitic protozoa
Trypanosoma cruzi with IC50 of 3.4 μg/ml.79
Cycloepoxydon was separated from the culture broth of deuteromycete 45-93.77 It
inhibited the TPA-induced NF-κB- and AP-1- mediated SEAP expression with observed IC50 of 1-2
μg/ml and 3-5 μg/ml, respectively.76, 80
Crews and Woods accomplished the total syntheses of (±)-panepoxydon and (±)isopanepoxydon.77 Mehta reported the synthesis of cycloepoxydon via an enzymatic kinetic
resolution of a racemic epoxyquinol.81 Porco reported the total synthesis of (-)-cycloepoxydon via
an asymmetric epoxidation mediated by tartrate (Scheme 18).82 The synthesis began with arene
18.1 which was accessed from commercially available 2, 5-dihydroxybenzaldehyde ($14 per gram

24

from Sigma-Aldrich) in 5 steps in 59% overall yield. Hypervalent iodine oxidation gave a
dimethoxyketal which was transketalized to 18.2. Tartrate mediated asymmetric nucleophilic
epoxidation and subsequent Stille coupling gave epoxide18.3, which was then reduced with DIBALH followed by acetal hydrolysis to yield epoxyquinol 18.4. Epoxidation of exocyclic alkene,
followed by tandem deprotection and cyclization gave (-)-cycloepoxydon in 13 steps overall with
13% yield. The epoxyquinol core was achieved in 11 steps with 28% yield from 2, 5dihydroxybenzaldehyde.
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1.4.6 Terremutin, Bromoxone, and Chaloxone

Terremutin was isolated from the fungus Aspergillus terreus.83 Synthesis of terremutin from
terreic acid confirmed the absolute configuration.84 Through a β-carotene-linoleate model assay
and an H2O2 radical scavenging assay, terremution was shown to have antioxidant activity
comparable with ascorbic acid.85
Bromoxone was isolated from a marine worm Phyllum hemichordata86 and was shown to
have antitumor activity.87 (±)-Bromoxone was synthesized by Taylor.88 The first enantioselective
synthesis of (+)-bromoxone came from Johnson’s group. They added bromine to p-benzoquinone
and reduced the resulting diketone with sodium borohydride to give dibromodiol 19.1 (Scheme
19). 89 The diol was then subjected to enzymatic resolution followed by silylation to give the
desired enantiomer (+)-19.2. Epoxidation followed by elimination of HBr and deprotection gave
(+)-bromoxone in 8 steps with 5% overall yield.
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Ryu reported the synthesis of (+)-bromoxone via the Diels-Alder strategy described above
(Scheme 10).39 (+)-Bromoxone was accessed by Schapiro via a route similar to one described
above (Scheme 14).90 Banwell also reported the synthesis of (-)-bromoxone.91
Chaloxone is a metabolite of the fungus Chalara microspora92 and is thought to be derived
from the shikimic acid pathway. Fex reported the synthesis of chaloxone in racemic form from
bromination of p-benzoquinone.93 No other syntheses or biological data have been published on
chaloxone.
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1.4.7 Jesterone

Jesterone was isolated from fermentation broth of the fungus Pestalotiopsis jesteri94 and it
displayed an interesting selective antimycotic activity toward the oomycetous fungi, which are
amongst some of the most plant pathogenic of all disease causing fungi.94 (-)-Jesterone has been
synthesized by Porco95 and (±)-jesterone by Mehta.96 The dimer of jesterone is a potential antitumor agent.97
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1.4.8 Epoxyquinol A, B, C and Epoxytwinol, Hexacyclinol, and Panepophenanthrin

Epoxyquinol A, B, and C and epoxytwinol are fungal metabolites isolated from an
unidentified soil fungus and they have demonstrated antitumor and antiangiogenic effects.98
Epoxyquinol A inhibits activation of the NF-κB transcription factor.99, 100 Epoxyquinol A,B, and C
inhibit angiogenesis by binding cysteine residues of receptor kinases and crosslinking them to
other proteins.101 They inhibit VEGFR2, EGFR, FGFR, and PDGFR.102, 103
Hexacyclinol was isolated from cultures of the fungus Panus rudis. It showed an IC50 of 1.4
μg/mL for L-929 mouse cancer cell line and an IC50 of 0.4 μg/mL for K562 leukemia cells. It also
demonstrated toxicity against HeLa cell lines with an IC50 of 10 μg/mL, meaning that it could
potentially be used to treat cancer.104 Panepophenanthrin was also isolated from Panus rudis and it
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inhibits ubiquitin-activating enzyme.105 The syntheses of this class of molecules have been
reported by several groups and the work will be highlighted below.
Osada and coworkers are credited for first identifying epoxyquinol A, B, and C and
epoxytwinol.99, 100, 103, 106 and they were also the first to report their total syntheses using a DielsAlder approach.98, 106-108
The syntheses commenced with a Diels-Alder reaction between furan and Corey’s chiral
sulfoxide auxiliary 20.1, which was produced in three steps from commercially available 2napthalenethiol, in 84% yield and moderate diastereoselectivity (Scheme 20).99, 109 Diels-Alder
adduct 20.2 was then converted to iodolactone 20.3 which was recrystallized to enantiopurity.
Iodolactone 20.3 gave endo epoxide 20.4 when treated with potassium hydroxide followed by
methyl iodide. β-Elimination driven by LDA gave cyclohexene 20.5. Epoxidation of alkene 20.5
was followed by reduction of the ester to the alcohol. Silylation gave bis-epoxide 20.6. TEMPO
mediated oxidation preceded isomerization with silica gel to give epoxyquinol 20.7. The
epoxyquinol core was accessed in 12 steps and 14% overall yield. Epoxyquinol 20.7 was protected
as the less sterically demanding acetonide derivative in order to achieve iodination in good yield to
give iodide 20.8. Suzuki coupling reaction with E-propenyl borate gave vinyl epoxyquinol 20.9 in
17 steps and 10% overall yield.

30

Alcohol 21.1 was then oxidized with MnO2 to give aldehyde 21.2, which exhibited an
equilibrium cycloisomerization to diene 21.3. Spontaneous Diels-Alder dimerization of 21.3 gave a
mixture of four products: epoxyquinol A was isolated in 24% yield, epoxyquinol B in 33% yield,
epoxyquinol C in 1% yield, and epoxytwinol in 8% yield. Epoxyquinol A is the result of an endoanti(epoxide)-anti(Me)-hetero Diels-Alder (Scheme 21), epoxyquinol B is from an exoanti(epoxide)-anti(Me)-homo Diels-Alder and epoxyquinol C is from an exo-syn(epoxide)-anti(Me)homo Diels-Alder. Epoxytwinol A is from a formal [4+4] cycloaddition of diene 21.3a .110
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This same Diels-Alder approach has been used by other groups to access the same
molecules. Mehta’s group employed an enzymatic resolution to access enantiopure 20.9111 while
Porco utilized a tartrate-mediated epoxidation to access the same compound.112 Porco also used
the tartrate epoxidation and the Diels-Alder strategy to synthesize (+)-hexacyclinol.113 Ryu
reported the synthesis of 20.9 through an asymmetric Diels-Alder approach.114
Kuwahara reported the synthesis of the epoxyquinols A-C using an asymmetric aldol and
Diels-Alder approach (Scheme 22).115 The synthesis commenced with an Evans asymmetric aldol
reaction between N-acyl-2-oxazolidinone 22.1 and senecialdehyde to afford the syn-aldol 22.2.
Chiral auxiliary 22.1 can be accessed in one step from commercially available (S)-4-benzyl-2oxazolidinone ($19 per gram from Sigma-Aldrich) in 99% yield.116 The aldol auxiliary was
reductively cleaved to give a diol which was then protected as disilylether 22.3. A Wacker
oxidation of the terminal alkene to a methyl ketone was followed by ozonolysis of the trisubstituted
alkene to give aldehyde 22.4. Ketoaldehyde 22.4 underwent an intramolecular aldol condensation
to give enone 22.5. Epoxidation of the alkene 22.5 gave epoxyquinol 22.6 . The Diels-Alder
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precursor 22.8 was completed by α-selenylation, oxidative elimination, bromination, Stille coupling
and deprotection to complete the 13 step synthesis in 22% overall yield.

Banwell reported the syntheses of both (+)-hexacyclinol and (+)-panepophenanthrine.117
The epoxyquinol element of each molecule was achieved via whole cell dihydroxylation of
iodobenzene.118 Epoxyquinol 23.1 is thought to be the biosynthetic precursor to (+)panepophenanthrin (23.2). Upon standing neat, 23.1 underwent quantitative dimerization to
afford (+)-panepophenanthrin (23.2). The methoxy epoxyquinol monomer 23.3 also dimerized
spontaneously to compound 23.4, which underwent presumably adventitious rearrangement to
(+)-hexacyclinol 23.5.
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Moses reported a similar synthesis of (+)-panepophenanthrin using enzyme mediated
desymmetrization to set the absolute configuration of the epoxyquinol monomer.119 (+)Panepophenanthrin was synthesized in Lee’s lab using a tandem metathesis approach.120
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1.4.9 Epoxyquinomycin C and D

Epoxyquinomycin C and D (Figure 12) were isolated from fermentation of the bacteria
Amycolatopsis sp.; epoxyquinomycin C was shown to have weak antibacterial properties.121 There
have been no syntheses reported for either molecule.

1.4.10 Cetoniacytone A and B

Cetoniacytone A and B are moderately active antitumor agents produced from Actinomyces
sp. strain Lu9419, an endosymbiotic bacteria isolated from the gut of the rose chafer insect Cetonia
aurata.41, 122 There have been no syntheses reported for either molecule
1.4.11 Fluostatin C and D
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Fluostatin C and D are the only two members of the fluostatin family which bear transepoxyquinol functionality.123 They were isolated from the culture broth of Streptomyces strain Acta
1383.123 Fluostatin C showed a mild inhibitory effect on the growth of the human tumor cell lines of
HMO2, HepG2, and MCF-7 while fluostatin D showed no activity.124
Enantioselective total syntheses of fluostatin C have been reported by Danishefsky125 and
Mehta.126 Danishefky used a Diels-Alder reaction to establish the core of the molecule (Scheme 24).
Ketone 24.3 was reduced with Superhydride and the epoxide was installed with Triton-B and tBuOOH (Scheme 24). Fluostatin B was constructed in 16 total steps (14 longest linear sequence)
and 3.4% overall yield.
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Mehta achieved the synthesis of fluostatin C using an enzymatic desymmetrization to
prepare diene 25.2. Diels-Alder reaction was followed by oxidation and desilylation, completing
the synthesis in 15 total steps (13 longest linear sequence) and 0.8% everall yield (Scheme 25).

1.4.12 Speciosin A and B
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Speciosin A and B are the only two compounds from a family of structurally similar
molecules that bear trans-epoxyquinol functionality. They were isolated from the fungal culture of
Hexagonia speciosa, which is common to the tropical and subtropical regions of China.127, 128
Racemic total syntheses of speciosin A and B were reported by Taylor via Pd-catalyzed
cross coupling, Diels-Alder, and diastereoselective epoxidation strategies.129

1.4.13 Pestaloquinol A and B
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Che and Zou recently reported the isolation and identification of two dimeric epoxyquinols
pestaloquinol A and B from the fermentation broth of the fungus Pestalotiopsis sp. taken off the
branches of the Kusamaki conifer Podocarpus macrophyllus.130 Cytosporin D is believed to be the
biosynthetic precursor of these unprecedented nonacyclic pentaketide structures. There have been
no syntheses reported for any of these molecules.
Of all the reported syntheses of the epoxyquinol moiety, there has not been a method
developed that is satisfactorily efficient. We sought to develop a strategy to access the intermediate
in a method similar to that reported for the racemic synthesis,21 which achieves the molecule in
four steps from p-benzoquinone
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CHAPTER 2. ASYMMETRIC TRANSFER HYDROGENATION
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2.1 Introduction
Simply put, a transfer hydrogenation is the transfer of the elements of hydrogen from a
donor to an acceptor. Reactions that can be considered transfer hydrogenation are: intramolecular
hydrogen migrations, hydrogen disproportionation between identical acceptor and donor, and
transfer hydrogenation-dehydrogenation between distinct donor and acceptor units.131 The latter
classification, and more specifically transfer hydrogenation between ketones and alcohols, will be
the focus of this review.
The classic example of the transfer hydrogenation of C=O bonds, the Meerwein-PonndorfVerley (MPV) reduction, is the transfer of hydrogen from an alcohol to a ketone catalyzed by an
aluminum oxide, usually aluminum isopropoxide (Figure 17).132 The reverse reaction, oxidation of
alcohols to ketones in acetone, is the Oppenauer (O) oxidation.133

MPV-O reactions proceed through a concerted direct hydrogen transfer mechanism, in
which both hydrogen acceptor and donor are coordinated to the metal center and hydrogen is
transferred directly from donor to acceptor (Figure 18).134 Direct hydrogen transfer is one of three
reaction mechanisms that have been proposed for the transfer hydrogenation of ketones.135, 136
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The second transfer hydrogenation mechanism proceeds through a stepwise hydridic route
(Scheme 26).135 The first step is the generation of metal hydride 26.2 from reaction with i-PrOH,
which coordinates an alcohol and transfers the hydride to form a ketone 26.4. Most transition
metal based catalysts for the hydrogenation of ketones with H2 gas proceed via the hydric
mechanism.137

The third and most recently proposed mechanism is metal-ligand bifunctional catalysis
(Figure 4).136 Unlike the two other mechanisms, neither the hydrogen donor nor the acceptor
coordinates directly to the metal center. Rather, hydrogen transfer occurs in the outer coordination
sphere of the metal center, through a six-membered, cyclic transition state (Figure 19).

A significant drawback to traditional aluminum alkoxide MPV reactions is that the metal
exchanges ligands too slowly to be used in catalytic amounts.138 Therefore, stoichiometric amounts
of the oxides are generally required. Also, there are very few successful asymmetric reports of
traditional MPV reactions. The few examples report low enantioselectivities and rely on the use of
chiral alcohols as reductants.138
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It wasn’t until chiral lanthanide and transition metal alkoxides were investigated that
significant asymmetric catalytic MPV reductions were reported.138 In 1993, Evans reported the
MPV reduction of acetophenone in i-PrOH at 96% ee with 5 mol % catalyst generated in situ from
SmI3, styrene oxide, and benzylamine.139 Also in 1993, Genêt reported the reduction of
acetophenone in i-PrOH using 1 mol % (CBD)2Ru(Br)2-NaOH with 62% ee.140 In 1994, De Graauw
reported the reduction of acetophenone with 33% ee using 1 mol % La(OtBu)3 and 1,2:5,6-di-Oisopropylidene-D-mannitol as ligand in i-PrOH.141 Although some catalysts showed good
conversion and decent enantioselectivity, they suffered from very limited scope. Most MPV
methodologies were generally limited by low enantioselectivity and low catalyst activity.137
Examples of non-MPV asymmetric transfer hydrogenations (ATH) of ketones are also
sparse in the literature prior to the mid 1990’s. The few examples suffered from limited scope and
poor enantioselectivities. The first report on the subject used [H4Ru4(CO)8((-)-DIOP)2] to reduce
aryl alkyl ketones with low enantioselectivity.142 Graziani reported the reduction of several aryl
alkyl ketones in the presence of dichlorobis(1,4-cyclooctadiene)diiridium- chiral phosphines,
isopropanol, and strong base in high yields and good enantioselectivity,143 and also reported similar
reductions employing rhodium based catalysts.144 Heil demonstrated the enantioselective
reduction of several aryl alkyl ketones with rhodium and iridium catalysts bearing 2,4bis(diphenylphosphinoxy)pentane and either cyclooctane or 1-5 cyclooctadiene ligands in basic
isopropanol.145 Bhatnagar reported similar reductions using chiral phosphine iridium
complexes.146 Alper was able to use [Ru(C6H6)Cl2]2 in the presence of Schiff bases as chiral ligands
to effect transfer hydrogenation of aryl alkyl ketones in i-PrOH and KOH with moderate
enantioselectivity.147
Bäckvall et al. demonstrated that RuCl2(PPh3)3-NaOH could catalyze the reduction of
ketones in i-PrOH. However, this catalyst demonstrated low chemoselectivity, delivering hydrogen
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to alkenes as well as to ketones.148, 149 In 1995, during a screen to identify chiral ligands to complex
with [Rh(C6H10)Cl]2, Lemaire observed that the chiral diamine ligand N,N-dimethyldiphenylethylenediamine with KOH as basic cocatalyst formed a complex that reduced
acetophenone with 67% ee at a catalyst loading of 5 mol %.150
Early development in the field of asymmetric transfer hydrogenation was slow because
most of the non-MPV catalysts that were being investigated bore aprotic ligands that tended to
drive the catalysts through a hydric mechanism137 The hydric mechanism requires coordination of
the carbonyl oxygen directly to the metal center, which forces the delivery of hydride through a
geometrically unfavorable pathway (Figure 20a).151 Noyori hypothesized that protonation or
hydrogen bonding to the carbonyl oxygen atom might facilitate the π-face attack of a nucleophile
attached to the metal center.151 In order for hydrogen bonding to effectively assist in delivery of the
hydride, a protic ligand should be employed. The ligand/substrate hydrogen bonding could
facilitate hydride delivery and produce the alcohol directly through a more favorable pathway
(Figure 20b).151

Most transfer hydrogenation catalysts, prior to 1995, contained neutral aprotic ligands.
Some examples of these include; tertiary phosphanes, tertiary amines, ethers, phosphites, dienes or
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anionic ligands.151 The use of neutral protic ligands was largely uninvestigated and Noyori was
curious as to whether the inherent characteristics of protic ligands could play an active role in the
catalytic cycle. Figure 20 illustrates a possible hydrogen-bond-assisted hydride transfer from M to
a carbonyl carbon atom utilizing a protic ligand. The LH-OC hydrogen bond facilitates the
interaction between the π face of the carbonyl group and the metal hydride.151 Some of the most
popular ligands for transfer hydrogenation are primary or secondary amines. An amine N-H proton
is not an inherently good hydrogen bond donor, but when bonded to a metal center their
characteristics can change drastically. An interesting example is the origin of the anticancer activity
of cisplatin (Figure 21) and its analogs, which use ammonia, primary amines, and secondary amines
but never tertiary amines as ligands.151
When the nitrogen atom of cisplatin interacts in cells, the acidity of the NH proton is high
enough to allow for its interaction with a phosphate moiety in DNA.151 The double-helix is
perturbed which allows the platinum center to complex with a guanidine, thus exhibiting antitumor
activity.151

In 1995, Noyori’s group reported that a catalyst mixture consisting of [RuCl2{(S)BINAP}(DMF)], chiral 1,2-diamine, and KOH was much more selective towards the asymmetric
hydrogenation of ketones than typical coordinatively unsaturated BINAP-Ru catalysts.152, 153 This
defined the conceptual turning point for the field of catalytic ATH. Noyori’s lab soon developed the
novel class of RuII catalyst that have come to dominate the field. (S, S)-Ru-TsDPEN (Figure 22)
bearing monotosylated 1,2-diamine and an η6-arene ligand is currently the gold standard of the
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field and effectively mediates the transfer hydrogenation of a broad range of aryl ketones from
isopropanol or HCO2H/NEt3 mixtures in excellent yields and enantioselectivities often exceeding
99:1 er.137, 154-157

The mechanism through which ATH catalysts are thought to proceed is dependent on a
protic ligand and is best summarized by a term coined by Noyori: ligand-metal bifunctional
catalysis.136, 153, 158, 159 Noyori and Ikariya’s contributions opened the field up to vigorous
exploration from many different research groups, and since then, a variety of new catalysts have
been reported. Catalysts have been ligated with bidentate ligands including diamines160, β-amino
alcohols156, 161-165, aminophosphines166, aminoethanethiols167, 168 o-aminomethylphenyl,169
tridentate ligands,170, 171 and tetradentate ligands.172 The most successful of these ligands are
capable of ligand-metal bifunctional cooperation.159 Another important feature of these protic
ligands is that many are available in either enantiomer, meaning that the desired enantiomer of the
resultant alcohol can be obtained by simply switching the absolute configuration of ligands. The
most efficient types of these chiral ligands have a stereocenter in close proximity to the nitrogen
atoms. The 16e ruthenium complex (Figure 23) has a 1, 2 anti-relationship between stereocenters
on the protic ligand which is optimal for high enantioselectivity of ATH reactions.173
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The catalyst is capable of accepting two hydrogens from a stable source and delivering them
in an enantioselective fashion (Figure 24).174-176 Investigation into ATH has exploded in the last two
decades and the volume of work is impressive to say the least. Several reviews of ATH cover the
field thoroughly.135, 137, 153, 159, 175, 177-185 Therefore, this work will be concerned with bringing the
reader up to the state of the art of ATH rather than serving as an exhaustive review.

2.2 Ruthenium

Three metals have played a significant role in ATH: ruthenium, rhodium, and iridium.
Ruthenium is by far the most popular metal in ATH. Monotosyl diphenylethylenediamine (TsDPEN)
is the most widely used protic ligand and p-cymene is the η6-arene ligand with the broadest
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application. We will use Ru(p-Cy)TsDPEN, (Figure 25) or simpler analogs, as a representative
example to explore details regarding mechanism and enantioselectivity.

2.2.1 Mechanism
The mechanism of Ru-catalyzed ATH has been extensively investigated. Computational
analysis161, 186, 187,188 as well as kinetic and isotope labeling studies157, 189 have established a generally
agreed upon mechanism that involves a six-membered pericyclic transition state (Scheme 27).136,
151, 175, 177, 181, 186, 190, 191

The active oxidizing form of the catalyst is the coordinatively unsaturated

16e square planar amidoruthenium complex 27.1. The non-tosyl N-Ru bond is equivalent to a
double bond with nitrogen’s lone pair of electrons contributing to the partial double bond.158 The
N-Ru bond of 16e 27.1 readily dehydrogenates a stable H2-source such as isopropanol or
trialkylammoniumformate through transition state 27.2 and is reduced to saturated 18e
aminohydride 27.3, as a single diastereomer, with a skewed octahedral configuration around
ruthenium.158 The N-H proton on 27.3 then hydrogen bonds with the ketonic oxygen, which
initiates the concerted transfer of hydrogen (27.4) to a single face of the carbonyl.136 Since the
catalyst can either accept or donate hydrogen, the reaction is reversible191 and unsaturated
amidoruthenium complex 27.1 is regenerated in every catalytic cycle.153 This mechanism is
differentiated from other hydrogenation reactions in that the reaction takes place in the outer
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coordination sphere of the metal. Formation of new C-H and O-H bonds occurs via metal-ligand
bifunctional catalysis, rather than by the hydridic route.174, 192-194

For most applications, i-PrOH can serve as a safe and cheap source of hydrogen. However, a
serious drawback of i-PrOH as hydrogen source is the reversibility of the reaction. Acetone
generated from dehydrogenation can continue to participate in the catalytic cycle, which can lead to
low conversion and as well as erosion of enantiomeric purity if the reaction mixture is left exposed
to the catalyst for extended periods of time.153 The reversibility can be mitigated by applying mild
vacuum to distill off generated acetone and replenishing with fresh i-PrOH. However, this reduces
the operational simplicity of ATH. Alternatively, triethylammonium formate can serve as an
efficient hydrogen source. The byproduct CO2 can be more easily removed from the reaction
mixture, effectively making the reaction irreversible.190 Another recently reported source of
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hydrogen for ATH is HCOONa/H2O which can be used with water as solvent. Several catalysts have
been shown to have high activity and enantioselectivity for the reduction of aryl ketones in aqueous
media.159, 195
2.2.2 Enantioselectivity
Factors determining the enantioselectivity of ATH are not as universally agreed upon as the
mechanism and are the source of some debate. It is worth noting that all rationalizations
concerning enantioselectivity were made using acetophenones as ketone. Some hypotheses
concerning the source of asymmetric induction include sterics, solvent and electrostatic effects,
dispersion forces, and a CH/ interaction between the arene ligand and the aryl ketone.196
Besides participating in the transition state, a primary function of the chelating ligand in
Noyori ATH catalysts is to establish the absolute configuration of the Ru stereocenter in the 18e
aminohydride 28.1. In the case of (S,S)-Ru(diphenylaminoethanol)(Scheme 28), the bulky phenyl
rings tend to adopt an equatorial orientation, resulting in ring geometry that confers an R
configuration at the new Ru stereocenter.186 The Ru-H aligns with the neighboring axial N-Hx
proton and a hydridic-protonic attraction helps to stabilize the alignment between H and Hx
(28.3).186 The ketone approaches the catalyst with the bulky substituent pointing away from the
phenyl rings of the amino alcohol ligand. Observed transition state energies were significantly
lower when the aryl ring of acetophenone was aligned with the η6-arene ligand of the catalyst,
which could be the result of a favorable CH-π interaction.186 Hydrogen bonding between the ketone
and the N-H proton initiates ATH.186
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What remains to be answered is why a high level of enantioselectivity is observed for ATH
of aryl ketones and ynones, but not for aliphatic ketones. Extensive computational studies
indicated that with (S,S)-RuTsDPEN, reaction takes place at the Re face of acetophenone which,
counter intuitively, puts the bulky phenyl group on acetophenone closer to the η6-arene ligand to
give the more sterically congested transition state 26.1 as opposed to the less crowded Si-transition
state 26.2 which has a methyl group in close proximity with the η6-arene ligand (Figure 26).186
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Noyori concluded on the basis of MP2 and B3LYP calculations that the sense of
enantioselectivity seen in the transfer hydrogenation of aryl ketones comes from a favorable CH/π
interaction between the η6-arene ligand on Ru and the aryl substituent of the ketonic substrate.136,
157, 186

The main forces thought to be involved in this interaction are electrostatic and also include a

charge-transfer component.197 Arene ligands with multiple alkyl substituents lead to higher er’s,
albeit at an expense to reactivity. The benefit comes from stabilization of the transition state which
is thought to be due either to the increased ability of π-donation into the favorable C(sp2)H/π
interaction or from a secondary C(sp3)H/ interaction between alkyl substituents on η6-arene
ligand and the aromatic element of acetophenone (Figure 27).182 A similar argument, proposing
that C-H/π interactions between η6-arene ligand and alkyne help stabilize the transition state, was
made by Cossy to explain the high enantioselectivities observed for Noyori reduction of ynones
(Figure 28).198
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Andersson et al. was skeptical that the electrostatic forces behind a CH/π interaction would
be strong enough to be the main factor in determining enantioselectivity and so he initiated a study
using a combination of B3LYP and LANL2DZ calculations.197 He argued that the major source of
enantioselectivity was actually a delicate balance of dispersion interactions and solvation effects,
with sterics and electrostatics also contributing. This balance is affected by both the η6-arene
ligand and by the amine ligand on the catalyst.197 Unfortunately, these effects only apply to aryl
ketones; aliphatic systems generally suffered from poor enantioselectivities. The study did not
include ynones.
Meijer and Handgraaf conducted calculations using an explicit methanol solvent model
(Figure 29, 29.1).174 They showed that the solvent may play an active role in the transition state
via hydrogen bonding to both the amine and the substrate oxygen, thereby lowering the energy of
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the transition state. Involving a solvent molecule directly in the reaction pathway challenged the
widely accepted six-membered transition state. They suggested that the mechanism of the reaction
in solution might be quite different from that in gas phase and that calculations that do not include
an explicit solvent will fail to observe important mechanistic details.

Xiao et al. conducted a similar study of the ATH in water (Figure 29).192 An explicit water
molecule was shown to hydrogen bond to the carbonyl oxygen thereby lowering the transition state
(29.2). They also noted a distinct pH effect on the reaction; the reaction was slow when the pH was
both low and high but enantioselectivity suffered only at low pH.199 They observed that as the
concentration of HCO2H relative to NEt3 increased, rate and enantioselectivity decreased. When pH
was low (HCO2H:NEt3 4.6:1), conversion dropped to 39% in 150 h and 80% ee for reduction of
acetophenone, compared to >99% conv. in 5 h and 97% ee for the optimized condtions (0.2:1
HCO2H:NEt3). They argued that the cause of the poor catalyst performance can be explained
through a mechanism where both the Tosyl N and ruthenium center are protonated in acidic
conditions leading to cleavage of the chelate bond. Without the structural stability of the chelate,
the catalyst is presumably driven into a less active and less enantioselective catalytic cycle. (Scheme
29) While this alternative mechanism does justify Xiao’s results, there is no direct evidence to
support it, and the theory has not yet been adopted by the ATH community.
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2.2.3 Noyori’s Catalyst Scope
One general structure of the RuII based ATH catalyst (Figure 30) dominates the literature; it
exists as the pair of 16e amido complex 30.1 and 18e hydridoamine 30.2. Very few successful
examples depart from this basic structure.173 Within this generic framework there has been an
amazing amount of diversity in ligands.

A full review of the various ligands employed in ATH is beyond the scope of this document.
However, some of the most successful ligands (er > 90:10 in reduction of acetophenone) are shown
below (Figure 31). Some important points to note are that protic ligands are required for the
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respective catalyst to participate in metal-ligand bifunctional catalysis. Of all ligands, 1,2 amino
alcohols such as 31.1, 31.3, 31.4, 31.5, and 31.7 and N-monotosylated diamine ligands such as
31.2 and 31.6 are the best in terms of activity and enantioselectivity toward the reduction of
acetophenone in i-PrOH. However, when formic acid is the hydrogen source, the 1,2-amino
alcohols are completely unreactive while the diamine ligands still show good activity.182

To form the catalyst, protic ligand 30.1 is mixed with η6-arene Ru dimer 30.2 in the
presence of NEt3 to form 18e chloride 30.3, which is treated with KOH to form the 16e catalysts
30.4 (Scheme 30)157 Alternatively, 16e catalyst 30.4 can be formed directly by combining
diamine 30.1 with Ru dimer 30.2 in the presence of strong base, which is often done in situ.157, 182
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Different combinations of η6-arene and diamine ligands have given rise to a considerable
amount of diversity in these catalysts (Figure 32), of which Ru(p-Cy)TsDPEN has proven to be the
most robust in terms of reactivity and enantioselectivity and has also been shown to have the
broadest substrate scope.200
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Ru(p-Cy)TsDPEN has been shown to effect the ATH of numerous aryl ketones and ynones in
good yield and high enantioselectivity (Figure 33).158 However, Ru(p-Cy)TsDPEN, like most ATH
catalysts, suffers from the inability to reliably and efficiently reduce aliphatic ketones
asymmetrically. There have been scattered reports of catalyst systems capable of asymmetrically
reducing certain dialkyl ketones, but most examples suffer from low conversion, poor
enantioselectivity, or narrow substrate scope;159 relevant examples will be discussed below.

2.2.4 Efforts Toward ATH of Aliphatic Ketones
2.2.4.1 RuII-Oxazoline
A novel and interesting RuII catalyst, developed independently by Sammakia201 and Uemura202, 203
is RuCl2(PPH3)(oxazolinylferrocenylphosphine) 31.1 (Scheme 31). It showed enantioselectivity
and turn-over rates comparable to Noyori’s catalyst for a broad range of aryl alkyl ketones.159, 204
Catalyst 31.1 was also able to reduce pinacolone to t-butylmethylalcohol 31.3. and 2,2dimethylcyclohexanone to 2,2-dimethylcyclohexanol 31.6 with unprecedented er’s of 99:1, albeit
with moderate TON’s and TOF’s. Interestingly, the sense of enantioinduction observed for dialkyl
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ketones was opposite that for aryl alkyl ketones. Uemura proposed that steric repulsion between
the phenyl ring of acetophenone and the phenylphosphine ligands in the transition state were
responsible for determining the absolute configuration of the aryl alkyl alcohols. For dialkyl
ketones, they observed a trend between the bulkiness of the alkyl group and enantioselectivity (tBu > c-hexyl > n-hexyl) and suggested that enantioselectivities were also the result of sterics.182
The author did not comment on the reversal of enantioselectivies. However, given what is known
about the mechanism of Noyori’s ATH catalyst,136, 174 one could assume that factors such as: CH-π
interactions between aryl groups on the catalyst and the substrate, solvent or electrostatic effects,
or dispersion forces might be contributing. Although reviews covering asymmetric ATH of
dialkylketones praise catalyst 31 for its ability to reduce certain dialkylketones,159, 182 low substrate
scope and low activity limit its usefulness.

2.2.4.2 Cyclodextrin
A RuII catalyst complex built from β-cyclodextrin that had been modified to bear amino
alcohols 32.1 was able to promote the ATH of aliphatic ketones in water using HCOONa as
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hydrogen source (Scheme 32).205 The catalyst was proposed to differentiate between the Re and Si
faces of prochiral methyl alkyl ketones through a preordering within the hydrophobic cavity of the
β-cyclodextrin.159 Enantioselectivity was observed to improve as the carbon chain was lengthened
(32.2 vs. 32.4 and 32.3 vs. 32.5). The catalyst displayed good enantioselectivities and yields for a
number of aliphatic ketones but suffered from low S/C ratios. The catalyst also requires that one
side of the ketone be significantly more hydrophobic than the other in order for it to distinguish
between the prochiral faces. A final drawback of catalyst 32.1 was the synthesis of the βcyclodextrin aminoalcohol, which was nontrivial.

2.2.4.3 Tethers
Another strategy to improve the enantioselectivity of aliphatic ketones is the installation of
a tether. After several generations of catalysts, Wills demonstrated that a three atom tether linking
the arene ligand to non-tosyl nitrogen resulted in a catalyst (33.1) with faster reduction rates and
higher S/C ratios than untethered Ru(p-Cy)TsDPEN (Scheme 33).206 The bulky alkyl aryl ketones
33.1 through 33.6 were reduced in better yield and higher enantioselectivity with 33.1 than with
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the untethered variant. The catalyst also reduced cyclohexyl-methyl ketone 33.7 in 80:20 er which,
at the time, was the highest reported er for the reduction of that substrate for any Noyori type ATH
catalyst. He reasoned that if the aryl ketones gave the R enantiomer because of a favorable CH/π
interaction, the switch in enantioselectivity for dialkyl ketone 33.7 was due to steric control in the
transition state. Alkyl tethered catalysts offer benefits in terms of activity and enantioselectivity of
alkyl ketones but they are more difficult to synthesize.

Wills and Ikariya have both reported a new catalyst (Figure 34) with an ether tether that
has similar, if not improved, catalytic activity compared to alkyl tethered 33.1.207, 208 The ether
tether offers an improvement over the alkyl tether owing to its increased simplicity of synthesis.
Namely, a Birch reduction is avoided in the ether synthesis. The exact reason for the increase in
enantioselectivity observed with tethered catalysts is not fully understood, but the tethers are
thought to give increased structural rigidity to the catalysts which is thought to improve ligand
cooperation, therefore improving their activity and enantioselectivity compared to non-tethered
catalysts.159, 207, 208
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2.2.5 Summary
To date, ruthenium remains the dominant metal used for ATH catalysts. Although,
significant strides have been made in improving catalyst design, there is still much work left to be
done is terms of developing more advanced catalysts for the asymmetric reduction of dialkyl
ketones.
2.3

Rhodium and Iridium
Rhodium and iridium are most commonly encountered in catalysts for the hydrogenation of

ketones with H2. However, several catalysts constructed around rhodium or iridium have
demonstrated the ability to mediate ATH reactions and they are worth mentioning. It is convenient
to cover these two metals together due to the similarities in the ligands employed. Typical catalysts
are constructed from chelation of TsDPEN to Cp* Rh and Ir dimers (figure 35).209 Rh (35.1, $582
per g, Sigma-Aldrich) and Ir (35.2, $460 per g, Sigma-Aldrich) come at a significant cost
disadvantage to the analogous Ru dimer ([{p-Cy}RuCl2]2 $35 per g, Sigma-Aldrich). High cost is
obviously a significant drawback to Rh and Ir in ATH compared to Ru.
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Some of the most common rhodium and iridium catalyst are analogues of Ru-TsDPEN, although
they bear Cp* η5-arene ligand as opposed to η6 ligands.153 In 2008 Xiao showed that Cp*Rh-TsDPEN
34.2 had superior activity and enantioselectivity for the reduction of acetophenone in water than
Ru-TsDPEN 34.1, while Ir-TsDPEN 34.3 was slightly lower in enantioselectivity (Scheme 34).209
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Adolfsson developed an analog of the TsDPEN ligand which has a long aliphatic chain at the
para position of the tosyl arene to be used in aqueous media in the presence of sodium
dodecylsulfate (SDS)(Scheme 35).210 They hypothesized that the long hydrophobic chain of the
modified catalyst would be forced into micelles formed by SDS in water. The polar metal end of the
catalyst would orient toward the hydrophilic surface while the long alkyl tail would align toward
the hydrophobic center. They hoped that this alignment would help the catalyst discriminate
between the enantiotopic faces of aliphatic ketones within the micelles thereby increasing
enantioselectivity. They did in fact observe moderate enantioselectivities for a number of aliphatic
ketones. Whether or not the enantioselectivities were the result of interactions between catalyst
and surfactant is unknown.

64

Wills used a tethered rhodium catalyst for the ATH of several aryl ketones to reduce
hydroxymethyl, chloromethyl, and phenoxymethyl aryl ketones with much higher activity and
enantioselectivity than both the untethered version of 36.1 or Ru(p-Cy)TsDPEN (Scheme 36). 211

After the positive results that Will’s group observed with the tethered Rh-TsDPEN catalyst
36.1, they identified the Ts-cyclohexyldiamine (TsDAC) ligand as a strong candidate to construct a
tethered variant around. Tethered catalyst 37.1 displayed short reaction times, excellent
conversions, and high enantioselectivities for a broad range of aryl alkyl ketones and a dialkyl
ketone in either organic solvent or water (Scheme 36).212 The catalyst was also extremely stable
and long lived. It was able to convert 100% of 2-acetylfuran to the R-alcohol at S/C = 10,000 over 7
days in water without any decrease in enantioselectivity (99:1 er). It was able to reduce
methylcyclohexylketone in excellent yields and with the highest enantioselectivity yet observed for
an ATH reaction.
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Arguably, the most important role that rhodium and iridium will play in the future of ATH is
as catalysts for reductions in aqueous media.159 Rhodium catalysts especially, have displayed some
of the highest activities and enantioselectivities for ATH of ketones in water. Additionally, rhodium
and iridium ATH catalysts are not O2 sensitive and do not require the degassing of water prior to
the reaction, nor do they require an inert atmosphere.159
2.4 Sustainability and the Future
Like all industries, chemistry is being affected by the ‘greening’ of society. Recent advances
in chemistry are often driven by the quest to find environmentally friendly and sustainable reaction
conditions. Chemists are exploring reaction conditions and reagents that are safe, efficient, and
environmentally benign.213 Economic and environmental pressures have pushed researchers
toward developing catalysts made from non-toxic and abundant metals.214 A major approach
toward this effort in ATH reactions lies in the use of iron based catalysts.215 Since solvents account
for a large amount of chemical waste generated, chemists are always seeking reaction media with
lower environmental impacts and some consider water to be such a solvent.
2.4.1 Water
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Initial research of ATH in water focused mainly on organic/water biphasic systems; the
primary interest of the field was modifying ligands in order to develop water soluble catalysts,216, 217
which resulted in catalysts with disappointing activities and/or enantioselectivities. In 2004, Xiao
discovered that Ru-(p-Cy)-TsDPEN, without any modifications, could reduce acetophenone
quantitatively in neat water with HCO2Na in 98:2 er.218 They soon discovered that [RuCl2(p-Cy)]2,
[Cp*IrCl2]2, or [Cp*RhCl2] could combine with numerous other traditional ATH ligands, designed for
use in organic solvents, to form catalysts that are effective for ATH in water without any further
modification.159
In general, for the reduction of acetophenone, monotosylated diamine ligands were shown
to be efficient and enantioselective for ATH in water while monocamphor-sulfonated diamine
ligands gave the best enantioselectivities. Rh catalysts have shown the best performance in terms
of rate and enantioselectivity.159 The best example to date of the successful aqueous ATH of a
dialkyl ketone is Will’s reduction of cyclohexylmethylketone with 100% conversion and 92:8 er
using catalyst 37.1 (Scheme 37).

2.4.2 Iron
Since ruthenium has been shown to efficiently effect ATH reactions, it is not unreasonable
to hope that iron might also be a suitable metal for ATH catalysts. Iron is significantly cheaper,
found in greater abundance, and is much more environmentally benign than ruthenium, rhodium,
or many other transition metals, meaning that many benefits would be conferred if stable, active,
selective, and efficient catalysts could be designed around iron.215
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The first report of an iron catalyzed ATH came from Gao et al. 219 They showed that clusters
of (NHEt3)[Fe3H(CO)11] and chiral diaminophosphine ligands could reduce aryl alkyl ketones. The
reactions did not proceed to completion, but high enantioselectivities (97:3 er) were sometimes
observed, especially when the aryl ketones also bore large alkyl groups. They did not report X-ray
data for the catalyst structures (Scheme 38).

Morris reported the reduction of several aryl ketones with the preformed FeII tetradentate
complex 39.1 (Scheme 39).220 The reductions proceeded in high conversions and low to moderate
enantioselectivity.
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The dominant ATH product of α, β-unsaturated ketone 40.1 with catalyst 39.1 was
reduction of both C=C and C=O bonds. The er of saturated alcohol 40.3 (67:33 er) is consistent with
the reduction product of the saturated ketone, alcohol 39.5 (65:35 er, Scheme 40), which suggests
that, in the case where both bonds are reduced, the reduction of alkene precedes the reduction of
ketone thus indicating that the catalyst is more selective for alkene reduction. Reduction of minor
product unsaturated alcohol 40.2 was moderately more enantioselective.
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Intrigued by the ATH results seen with catalyst 39.1, Morris sought to improve the catalyst
by modifying the linkers between the nitrogen and phosphorus atoms to make them both shorter
and non-aromatic; DPEN was substituted for cyclohexyldiamine as chiral ligand.220 A major benefit
is that the modified catalyst 41.3 can be formed in one-pot (Scheme 41).

Catalyst 41.3 exhibited good conversion as well as moderate to good enantioselectivity for
the ATH of aryl alkyl ketones in i-PrOH with bulky alkyl substituents showing the highest
enantioselectivities. (Scheme 42).220 Catalyst 41.3 was able to reduce methyl isopropyl ketone to
alcohol 42.7 with an enantiomeric ratio of 75:25 in favor of the (S) enantiomer. However,
enantioselectivity was significantly lower for 4-phenyl-2-butanol 42.4.
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Catalyst 41.3 was also significantly more chemoselective than catalyst 39.1 for reduction of
ketones over alkenes (Scheme 43).220 Enone 43.1 was reduced to allyl alcohol 43.2 in 82% yield
with moderate enantioselectivity. Saturated alcohol 43.3 was isolated in only 4% yield with er
(63:37) intermediate between allyl alcohol 43.2 (er = 80:20) and reduction product of 4-phenyl-2butanol, saturated alcohol 42.4 (er = 57:43), suggesting that ketone reduction precedes alkene
reduction for at least a portion of the saturated alcohols. The lower enantioselectivity of alcohol
43.3 relative to allyl alcohol 43.2 could be due to the loss of a coordinating effect in cases where the
alkene is reduced first.
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An interesting class of catalysts was introduced by Reiser’s group in 2010 (Scheme 44).221
Bis-isonitrile ligands derived from chiral oxazolines were utilized to build a family of five catalysts
(differing only by substitution on the carbons between nitrogen and oxygen. The most active
catalyst 44.1 was tested toward the reduction of a variety of aryl alky ketones. An er of 82:18 was
reported for the ATH of acetophenone in iPrOH with high conversion, albeit modest
enantioselectivities.
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Wills continued exploration into ATH using iron cyclone complexes 45.1-45.6.222 They
made asymmetric variants of cyclone type iron catalysts developed in Casey’s lab.223 The catalysts,
most notably 45.3, reduced acetophenone in good conversion albeit poor enantioselectivity.223
(Scheme 45)

Gao and coworkers recently reported the chiral macrocyclic ligand 46.1 which bears
phosphorus and nitrogen donors (Scheme 46).224, 225
Ligand 46.1 with tri-iron [Fe3(CO)12] clusters showed high activity and excellent
enantioselectivity toward the ATH of a broad range of aromatic ketones. Neither electron
withdrawing nor electron donating substituents on the aromatic ring played a significant role in
enantioselectivity. However, when substrates had substituents in the ortho position, activity was
diminished. It was suggested that the added steric bulk around the ketone from the ortho
substituent led to the decrease in activity.
Although they did not propose a structure for the catalyst, they did suggest that the
macrocyclic structure of the ligand might increase the configurational stability of the ligand,
increasing the rigidity of the catalyst, thus giving rise to the observed enantioselectivities. Catalyst
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46.1 marks the first iron based catalyst that exhibited high enough TOF’s, TON’s and
enantioselectivities to be practically used in academic or industrial settings for the ATH of aryl
ketones.224

Conclusions:
Some fairly impressive work has been reported in the relatively young field of iron based
ATH catalysis, but there is much work to be done towards developing viable iron based catalysts.
However, systems based on ligands such as Gao’s macrocycle 46.1, offer hope for the future use of
iron in ATH reactions.

74

CHAPTER 3. STUDIES TOWARD THE SYNTHESIS OF ANTASCOMICIN B
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3.1 Introduction

Antascomicin B, a metabolite of a strain of the soil bacteria Micromonospora, shares
structural similarities with ascomycin, FK-506, and rapamycin. It also binds the immunophillin
FKBP12 as strongly as these molecules. However, unlike most other FKBP12 binding compounds,
antascomicin B does not demonstrate immunosuppressive activity. In fact, it actually antagonizes
the immunosuppressive effects of both FK-506 and rapamycin.226 FKBP12 was found to be present
in the brain and spinal cord in concentrations almost fifty times higher than in the immune system,
which suggests that immunophilins such as FKBP12 might play a critical role in the regulation of
the nervous system.10 Molecules such as antascomicin B, which strongly bind FKBP12 but do not
have immunosuppressive activity, could be potent chemotherapeutics toward neurodegenerative
diseases like Parkinson’s or Alzheimer’s.12,13
Antascomicin B, a 37 carbon complex polyketide with 12 stereocenters, is an interesting
and challenging synthetic target (Figure 36). It contains a 21 membered macrocycle which includes
lactone and lactam linkages, between C1 and C26 and between C2 and C7 respectively, a masked
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1,2,3-tricarbonyl on C7, C8, and C9, and a lactol bridge between C9 and C13. Antascomicin B also
bears an anti-anti-1,2,3-trihydroxycyclohexyl moiety on C34-C29, which is of primary interest to
the present work.

3.2 Ley’s Synthesis of the C25-C34 Fragment of Antascomicin B

The total synthesis of antascomicin B was reported by the Ley group in 2005 (Scheme 47).14
Their synthesis design consisted of the convergence of three fragments. The C25 epoxide on
fragment 47.2 was coupled with the C24 anion of fragment 47.3 to form the C10-C34 carbon
skeleton. The C10-C24 fragment was then joined to pipecolic acid fragment 47.1 via esterification.
Carbon-heteroatom bond macrocyclization formed the complete carbon skeleton which was the
oxidized and deprotected to give the natural product antascomicin B.
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The synthesis of C25-C34 fragment 47.2 is of particular interest to this work; especially the
establishment of the trihydroxycyclohexyl moiety. Synthesis of fragment 47.2 commenced with
protection of dimethyl (D)-tartrate 48.1 as diacetal 48.2 to set the anti-1, 2-diol configuration that
will eventually be on C31 and C32. Diacetal 48.2 was then converted to protected aldehyde 48.3.

Asymmetric crotylation of commercially available benzyloxyacetaldehyde 49.1 gave the
secondary alcohol with high enantioselectivity (Scheme 49), which was benzylated to alkene 49.2.
Reductive ozonolysis of alkene 49.2 gave an ozonide which was resistant to reduction by sodium
borohydride. Triphenylphosphine was added to convert the ozonide to the aldehyde, which was
reduced to primary alcohol 49.3. The primary alcohol was converted to iodide 49.4 which was
displaced by allylpyridylsulfide to give allylsulfide 49.5 and was subsequently converted to
allylstannane 49.6 through an anionic cuprate reaction.
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Addition of stannane 50.2 to aldehyde 50.1, mediated by zinc iodide, followed by protection
of the newly formed secondary alcohol and deprotection of primary alcohol afforded 50.3 (Scheme
50). The aldehyde/stannane addition proceeded to establish the third anti-hydroxyl group at C30
on the six membered ring, and gave a 7:1 diastereomeric ratio at C29 favoring the desired isomer.
Primary alcohol 50.3 then underwent Swern oxidation to aldehyde followed by a Wittig reaction to
produce alkene 50.4. Ring closing metathesis catalyzed by GrubbsII was followed by reduction of
the resultant endocyclic C=C double bond and simultaneous removal of both benzyl groups to give
the diol 50.5. The diol was subsequently epoxidized to C25-C34 fragment 50.6.
Ley’s convergent synthesis of the C25-C34 fragment required 19 overall steps with 24.7%
yield and a longest linear sequence of 15 steps. Two of the stereocenters on the
trihydroxycyclohexyl group were purchased as methyl tartrate and the synthesis required the use
of tin, ruthenium, and palladium.
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3.3 The McIntosh Group’s Synthetic Efforts Toward Antascomicin B

Our group has been engaged in the total synthesis of antascomicin B for a number of years.
The present work will highlight our efforts toward the synthesis of antascomicin B including: the
synthesis of an advanced model of the C34-C22 fragment, the racemic synthesis of the C34-C21
fragment, and the enantioselective synthesis of the C34-C25 fragment (Figure 37). We also
describe plans for the completion of the natural product.
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3.3.1. Retrosynthesis

Our current retrosynthetic analysis of antascomicin B involves the convergence of two late
stage intermediates: C34-C21 fragment 51.2 and C20-C1 fragment 51.2 (Scheme 51). We envision
bringing the two fragments together using Grubb’s metathesis and Yamaguchi lactonization. The
C20-C1 fragment 51.2 will be prepared from pipecolinic acid. Its synthetic route will include a
Suzuki coupling and an amino-Claisen rearrangement.

The C34-C21 fragment 51.1 will be accessed from reduction of alkene and partial
deprotection followed by Grieco olefination of the primary alcohol of 52.1 (Scheme 52). The final
C23 stereocenter in intermediate 52.1 will be set by allylic diazene rearrangement from enone
52.2, which is generated from homologation of vinyl iodide 52.3 to the enantiopure C34-C25
fragment 52.4.
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Key reactions in the synthesis of the C34-C25 fragment are an Ireland-Claisen
rearrangement, an allylic diazene rearrangement, a directed hydrogenation, and an asymmetric
transfer hydrogenation. A brief overview of the Ireland-Claisen and allylic diazene rearrangement
and how they apply to our strategies is included below in order to familiarize the reader with the
material.

3.3.2 The Ireland-Claisen Rearrangement

A major contribution to the Claisen rearrangement came in 1972 when Robert Ireland
discovered that, under relatively mild conditions, Li-enolate anions or more commonly, the
corresponding silyl ketene acetals of allyl esters could undergo a Claisen-like sigmatropic
rearrangement (Scheme 53).227
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This rearrangement has high value in synthesis for a number of reasons. First, the allyl
ester reactants are readily accessible from reaction of the respective allyl alcohol with an activated
carboxylic acid.228 Second, it is usually possible to control the E/Z geometry of the ester enolate.
This allows for predictable determination of the stereochemistry in resulting C-C bonds in the
rearranged product (Scheme 54).229

Our lab has developed a novel variant of the Ireland-Claisen rearrangement of bis-allylic
esters derived from cycloalkenones (Scheme 55).228, 230-232 In our variant, the carbinol center of the
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allylic ester is contained within a cyclohexyl ring. The silyl ketene acetal intermediate 55.2
rearranges to give alkylidene cycloalkene 55.3.

3.3.3 The Allylic Diazene Rearrangement (ADR)
3.3.3.1 Background

In its simplest form, the allylic diazene rearrangement (ADR) is the retro-ene reaction of cis1-diazo-2-propene to produce propene and molecular nitrogen (Scheme 56).233

Density functional theory studies have determined that the ADR occurs through an early,
concerted, six-member, cyclic transition state (Scheme 57).234

In 1964 Bumgardener and Freeman reported the reductive deamination of allylic amines by
treatment with difluoroamine to afford the alkene and two equivalents of the allylic amine
hydrofluoride salt. This report was the first to propose the now-accepted ADR reaction
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mechanism.235 The ADR is a pericyclic, 1,5-sigmatropic rearrangement that involves the suprafacial
transfer of the terminal diazene hydrogen to the terminal carbon of the alkene.
A common application of the ADR is as the final step in the reduction of an α, β-unsaturated
ketone or aldehyde to the reduced alkene (Scheme 58).236 Enone 58.1 was converted to sulfonyl
hydrazone 58.2 which was then reduced to hydrazine 58.3 with catecholborane, NaBH4 or
NaCNBH3 in an acidic medium. Upon formation of the allylic diazene, the ADR occurred
spontaneously to give the 1, 3-transposition product 58.4.236

3.3.3.2 The ADR and Cyclic Stereocontrol

The ADR has found great synthetic utility in relaying stereochemistry in cyclic systems,237
commonly through the reduction of α,β-unsaturated tosylhydrazones.238 Preparation of
tosylhydrazones generally occurs readily when ketones are treated with sulfonyl hydrazides in
refluxing ethanol of THF. One example from our lab is the synthesis of a cis-fused
hydroisobenzofuran bicycle 59.3 (Scheme 59)239
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3.3.3.3 The ADR and Acyclic Stereocontrol

Although there have been numerous examples of use of the ADR to install stereocenters in
cyclic systems,237, 240, 241, 242 achieving the same in an acyclic system presents different problems.
Prior our work, installation of an sp3 stereocenter in an acyclic system had not been reported. Our
lab demonstrated a method to establish either 1,4-syn or 1,4-anti stereorelationships using the
ADR.243 The 1,4-syn diastereomer of the ADR product was formed when E-alkene 60.1 was used
while Z-alkene 60.3 led to 1,4-anti isomer 60.4. Both isomers showed >20:1 dr (Scheme 60).
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We hypothesized that diastereoselective reduction of acyclic α,β-unsaturated hydrazone
61.1 proceeds through a Cram chelation controlled pathway to afford allylic diazene 61.2. If the
terminal carbon of the allyl group 61.1 is prochiral, the stereochemistry of the diazene will be
transferred to the terminal carbon via the ADR. In acyclic systems, allylic strain in intermediate
61.4 controls delivery of the hydrogen (Scheme 61).

Rosini found that when tosylhydrazones bearing α-alkoxy functionality were treated with
sodium cyanoborohydride, they gave exclusively anti-hydrazides while tosylhydrazones lacking αalkoxy functionality gave a mixture of anti and syn-hydrazides.244
Our group expanded on Rosini’s observation and applied a similar methodology to acyclic
α’-alkoxy-α,β-unsaturated tosylhydrazone 62.1 (Scheme 62). Treatment of hydrazone 62.1 with
catecholborane in the presence of silica gel gave the rearranged product with diastereoselectivity in
excess of 20:1. Reduction from the less hindered face afforded the 1, 2-anti hydrazine 62.4. Allylic
strain dictated hydrogen transfer of the ADR and created the new sp3 stereocenter in the 1, 4-syn
alkene 62.6.
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Both the 1,4-syn and 1,4-anti stereorelationships are found in a variety of marine natural
products, such as redispongiolide A and B, and amphidinolide J.245, 246 Antascomicin B possesses
both 1, 4-syn (C23-C26) and 1, 4-anti (C11-C14) motifs (Figure 38).226
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3.3.3.4 Model Studies of the ADR.

Our retrosynthetic strategy toward antascomicin B relies on the ADR to establish the
configuration at C23. Therefore, an appropriate model study was necessary to test the feasibility of
this transformation.
The synthesis of both E and Z-α, β-unsaturated enones began with the benzylation of
commercially available (S)-(+)-mandelic acid 63.1 (Scheme 63). The o-benzyl-acid 63.2 was
converted, via the mixed anhydride, to Weinreb amide 63.3. Lithio anion derived from vinyl iodide
63.4 was then added to amide 63.3 to give the α, β-unsaturated ketone 63.4, which was
subsequently converted to tosylhydrazone 63.5.

Using modified Kabalka conditions (catecholborane, silica gel, NaOAc-3H2O, reflux), the
reduction of α, β-unsaturated-E-hydrazone proceeded with high diastereoselectivity. Reduction
from the less hindered face produced 1, 2-anti-hydrazine 64.2 followed by ADR to afford 1, 4-synalkene 64.3 (Scheme 64).
89

3.3.4 Model Study of the C22-C34 Fragment

An advanced model of the C22-C34 fragment of antascomicin B was prepared by former
graduate student Wei Qi in order to test the feasibility of the Ireland-Claisen and allylic diazene
rearrangements.18 The first attempt at the model system proceeded from 6-hydroxycyclohexenone 65.1a (Scheme 65). The unsaturated ring showed much higher diastereoselectivity
in the addition of propynylMgBr than did the saturated compound (16.2b).

However, endocyclic alkene 65.2 proved unsuitable for the synthesis due to problems
encountered during the Ireland-Claisen rearrangement (Scheme 66). Ireland-Claisen precursor
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66.1 gave a mixture of products. When glycolate 66.1 was treated with KHMDS and then TMSCl,
1,4-diol 66.2 was major product. When base was added to allyl ester 66.1 in the presence of
TMSCl, acid 66.3 was the major product. We speculate that upon formation of enolate 66.4, a rapid
suprafacial [3, 3] O-to-O rearrangement occurred to produce enolate 66.5 which, in the presence of
TMSCl, underwent Ireland-Claisen rearrangement to give 66.3. In the absence of TMSCl, enolate
66.5 underwent ketene elimination to give 1, 4-diol 66.2.

To circumvent the undesired Ireland-Claisen rearrangement products, the synthesis of a
saturated analogue was pursued (Scheme 67). Addition of propynylMgBr to commercially available
2-hydroxy-cyclohexanone afforded anti-diol 67.2, albeit in an unselective fashion. The secondary
alcohol was silylated to 67.4 followed by acylation of the tertiary alcohol, to afford glycolate 67.5.
The next step in the synthesis was the partial-hydrogention of alkyne to Z-alkene to give IrelandClaisen precursor 67.6. Ireland-Claisen rearrangement was initiated by addition of LTMP to a
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solution of 67.6 and TMSCl in THF to afford pentenoic acid 67.7 with anti-configuration at C26 and
C27.

Acid 68.1 was converted to Weinreb amide 68.2 (Scheme 68), which underwent
homologation to the lithio anion of vinyl iodide 68.3 to yield α, β-unsaturated ketone 68.4. Ketone
68.4 was converted into hydrazone 68.5 followed by ADR to give alkene 68.6. Directed
hydrogenation via Crabtree’s catalyst set the C29 stereocenter and completed the synthesis of the
C34-C22 model compound 68.7. The model synthesis showed that the Ireland-Claisen and allylic
diazene rearrangements were indeed feasible transformations for the synthesis of the C34-C21
fragment of the natural product.
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3.3.5 Racemic Synthesis of the C34-C21 Fragment

The racemic synthesis of the C34- C21 fragment has recently been completed in our lab, led
by post-doc John Hutchison (Scheme 69). The synthesis began with Diels-Alder reaction between
p-benzoquinone and freshly cracked cyclopentadiene to afford Diels-Alder adduct 69.1, which was
then epoxidized to 69.2. Epoxide diketone 69.2 was then reduced racemically to give
monoreduced epoxide 69.3. Retro Diels-Alder reaction extruded cyclopentadiene to give
epoxyquinol 69.4, which underwent hydrolysis of epoxide ring to afford anti-anti cyclitol 69.5.

93

Bis-silylation of cyclitol 70.1 gave bis-silyl alkene 70.2, which underwent alkene reduction
to give cyclohexanone 70.3 (Scheme 70). Propynylation to alkyne 70.4 was followed by Boc
protection of the secondary alcohol to form mono alcohol 70.5. Acylation gave propargyl ester
70.6 which was then semi reduced to Z- alkene 70.7.
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When treated to standard Ireland-Claisen rearrangement conditions, the rearrangement of
allylic ester 71.1 could proceed through two possible transition states (Scheme 71). Transition
state 71.2b has a carbon bearing a protected hydroxyl functionality in the axial position, which
creates an unfavorable 1,3-diaxial interaction between the cyclohexyl silylether and the exocyclic
silylenolate. This steric strain is avoided in transition state 71.2a, which has the bulky silyl group
in the equatorial position. The reaction proceeded entirely through transition state 71.2a resulting
in rearranged pentenoic acid 71.3 in high yield.
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Pentenoic acid 72.1 was converted to Weinreb amide 72.2, which was in turn treated with
lithio ion derived from iodide 72.3 to form enone 72.4 (Scheme 72).

Enone 73.1 was then treated with tosylhydrazide to afford E-hydrazone 73.2, which
underwent ADR to give the 1,4-syn-alkene 73.3 (Scheme 73). Bis-silylether 73.3 was deprotected
to diol 73.4. We propose that the alcohol α to C29-C28 alkene directed Crabtree’s catalyst to effect
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diastereoselective reduction of alkene to set the C29 stereocenter. Concurrent reduction of the
C25-C24 alkene occurred to give the saturated C34-C21 fragment of antascomicin B 73.5. The final
Crabtree’s reduction proved quite problematic. It required functional group manipulation and very
high catalyst loading and it produced the desired product in low yield along with an inseparable
byproduct.
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3.3.6 Enantioselective Synthesis of the C34-C25 Fragment
3.3.6.1 Enzymatic Approach

We envisioned approaching the enantioselective synthesis of the C25-C34 fragment through
a route similar to the racemic synthesis. Therefore, we needed to develop a method to readily
prepare multi-gram quantities of epoxyquinol 39.1 (Figure 39). Our original route to epoxyquinol
39.1 followed a literature procedure reported by Ogasawara.247 The synthesis commenced with a
Diels-Alder reaction between p-benzoquinone and freshly cracked cyclopentadiene to give adduct
74.1 in moderate yield (Scheme 74). Diels-Alder was followed by diastereoselective Luche
reduction to afford meso-diol 74.2. Although the reduction has been reported on large scale,248 we
experienced difficulty scaling up the reaction beyond approximately three grams.
Desymmetrization occurred during the next reaction which was an enzymatic monoacylation to
monoacetate 74.3.
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Our initial attempts to replicate the enzymatic acylation gave poor yields (< 5%) and
complex reaction mixtures that were difficult to purify (Table 2). Eventually, through direct contact
with the corresponding author, it was determined that immobilized Amano lipase PS-D was
required for good conversion. Using one equivalent by weight of Amano lipase PS-D in a 10:1
THF:NEt3 solvent mixture, monoacetate 74.3 was obtained in 82% yield and greater than 99:1
enantioselectivity.
Table 2
Enzyme
lipase PS
lipase PS
lipase PS
lipase PS

Solvent
MeCN
MeCN
MeCN
MeCN:H2O 10:1

Time
16 d
16 d
16 d
16 d

Temp. oC
rt
28
40
rt

Yield
nr
nr
nr
nr

lipase PS

MeCN:H2O 10:1

16 d

28

nr

lipase PS

THF:NEt3 10:1

16 d

rt

4%

lipase PS-D

THF:NEt3 10:1

4d

rt

82%
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Secondary alcohol 75.1 was silylated to 75.2 (Scheme 75). Deacylation to alcohol 75.3
followed by oxidation gave enone 75.4 which was epoxidized to 75.5. Removal of cyclopentadiene
via retro Diels-Alder reaction gave silylepoxyquinol 75.6 in eight steps and 11% overall yield.

The enzymatic approach to epoxy quinol 75.8 suffers from tedious and inefficient
protection/deprotection and redox sequences, use of expensive or hard to obtain reagents, and lack
of scalability Therefore, we sought a more efficient approach comparable to the racemic synthesis.
A literature survey indicated that asymmetric transfer hydrogenation using Noyori’s
RuTsDPEN could offer a mild, scalable approach to enantiopure epoxyquinol 76.1 (Scheme 76).151
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In 1997, shortly after Noyori first introduced his catalyst, he reported the kinetic resolution
of several racemic secondary alcohols with RuTsDPEN in acetone.249 The majority of secondary
alcohols screened were aryl, however, they did report the enantioselective oxidation of Luche diol
77.1 using (S,S)-Ru(mesitylene)TsDPEN in good yield and high enantioselectivity (Scheme 77).
Noyori’s example encouraged us to explore catalytic asymmetric transfer hydrogenation as a way to
access enantiopure hydroxy enone 77.2.
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3.3.6.2 Asymmetric Transfer Hydrogenation
We were curious to see if we could reproduce Noyori’s result and so we proceeded by
constructing the catalyst precursor which we subsequently treated with KOH to form the active
catalyst (Scheme 78). The p-cymene-Ru dimer was chosen because it is significantly less expensive
than the alternative mesitylene dimer.157

Noyori’s experimental details were incomplete and he did not respond to direct
communication, so we replicated his conditions as closely possible. We exposed diol 79.1 to (S,S)Ru(p-Cy)(TsDPEN) in acetone (0.1 M) at a catalyst loading of 0.67 mol %. However, instead of
observing a kinetic resolution, we observed a mixture of unreacted starting material 79.1, parahydroxy phenol 79.2, diketone 79.3 resulting from over oxidation, and semi-saturated diketone
79.4 (Scheme 79). The two obvious mechanisms to explain the formation of semisaturated
diketone 79.3 are ketone reduction followed by isomerization250 or direct alkene reduction.
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These results were discouraging so we decided to examine the reverse reaction, therefore
we applied RuTsDPEN to the mono-reduction of diketone 80.1 (Scheme 80). We kept all reaction
condition the same as for oxidation of enediol 79.1 except for the solvent, which we switched to
isopropanol. The reaction resulted in diketone 80.2 as major product and hydroquinone 80.3 as
minor product.

Given these anomalous results, we decided to repeat Noyori’s example exactly by using
(S,S)-Ru(mesitylene)(TsDPEN) (scheme 81). Interestingly, the mesitylene based catalyst did indeed
produce hydroxyl enone 81.3, although in low yield and moderate enantioselectivity. The
reduction also produced all other byproducts observed in reduction from the p-cymene based
catalyst.
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3.3.6.3 No-D NMR
The fact that the mesitylene catalyst could effect monoreduction while the p-cymene
catalyst did not piqued our curiosity. We also wanted to understand more about the relative rate of
product formation. We initiated a series of No-D NMR experiments to probe the reactions
further.251 The experiments were conducted by setting up the reactions as usual, and then
transferring a small amount of the reaction mixture to an NMR tube. The reactions proceeded in
the NMR tube and scans were taken periodically to observe reaction progress.
In general, analyses were made by observing peaks in the 6-8 ppm region. This region of
the spectra contained peaks indicative of all observed products and was far enough removed from
solvent peaks so as to ensure reliable and reproducible identification of all species present.
Our first No-D experiment was the oxidation of meso-diol 82 using p-cymene catalyst. The
two large peaks on the t = 3 min spectra below labeled A correspond to the starting material; we
observed disappearance of the starting material as the reaction progressed. Interestingly, the first
product observed was hydroxyl enone B, but after one hour, enedione C was present in roughly
equal amounts. After 20 h, the reaction had proceeded to approximately 75% conversion with the
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predominant product being enedione C with hydroquinone D and hydroxyenone B in minor
amounts. Another interesting observation is that we never observed the semi-saturated diketone
81.5 in any of these No-D experiments.
Work up of these reactions involved removing solvent under rotary evaporation followed
by column chromatography. When No-D experiments using p-cymene catalysts were worked up
fully, we observed disappearance of monoreduced product B and appearance of semi-saturated
diketone 81.5. This observation suggests that monoreduced product C could potentially be
isomerizing to semisaturated diketone 81.5 when exposed to p-cymene catalyst during heating
while undergoing rotary evaporation.
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The mesitylene catalyst seemed to be more selective for formation of hydroxy enone B
(Scheme 83). However, after a day the reaction had only proceeded to roughly 20% conversion.
Neither diketone 81.5 nor hydroquinone 81.4 was formed in No-D experiments using mesitylene
catalyst. When the reaction mixture was concentrated and heated during rotary evaporation,
hydroxyl enone B survived and neither byproduct developed significantly.
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When enedione A (Scheme 84) was reduced with Ru(p-Cy)TsDPEN in isopropanol, diketone
B was present after only three minutes. After six hours, the starting material was exhausted and
the principle product was diketone B. No ketone reduction product was observed over the course
of the reaction. These results imply that either isomerization of keto alcohol to diketone is
extremely rapid, or that the alkene was reduced directly. Alkene reduction of certain enones as
well as activated alkenes lacking ketone functionality has been reported using the Noyori
catalyst.252
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3.4.2 ATH of Epoxy Diketone
During our studies on the ATH of α-β unsaturated meso-diketone and meso-diol, it became
evident that we would need to find another synthetic approach. We decided to explore ATH for the
desymmetrization of meso-diketone 85.1. Meso diketones have been desymmetrized by
asymmetric hydride reductions,253, 254 whole cell reductions,255-263 and asymmetric
deprotonations.264 Although Noyori reduction of an achiral diketone has been reported,265 to the
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best of our knowledge, it has not been employed to desymmetrize meso-diketones until our
efforts.20
We started exploring the use of ATH to desymmetrize meso-diketone 85.1 using
inexpensive i-PrOH as reductant and solvent. We were delighted to observe that monoreduction
did in fact occur and the Noyori reduction gave a single diastereomer, unlike the racemic reduction,
which gave approximately 6:1 dr.21 Initial attempts using a catalyst loading of 0.04% in i-PrOH
afforded the monoreduced epoxide in the modest enantiomeric ratio of 70:30 (Table 3). We were
eventually able to improve er to 85:15 by increasing the catalyst loading to 0.16 mol %. We later
found out (by comparison with de-silylated enzymatic product 75.6) that monoreduced alcohol
85.2 was in fact the incorrect enantiomer for our synthesis.

Table 3

a

Entry

Cat. Load (mol %)

1
2
3
4
5
6

0.04
0.04
0.08
0.08
0.16
0.08

Temp
(°C)
23
0
0
-60
0
23

7

0.16

23

i-PrOH
“
“
“
“
“

Time
(h)
1
12
7
24
5
2

70:30
80:20
80:20
no rxn
80:20
80:20b

“

2

85:15b

Solvent

era

er was determined by chiral GC. bsubstrate was added over 10 min as a solution in CH2Cl2.
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Since ATH in i-PrOH is reversible,190 optical purity can deteriorate if reactions are allowed
to proceed over extended periods of time. In order to eliminate reversibility in hopes of improving
the enantioselectivity of the reduction, we investigated the use of formic acid and trialkylamine
base as reductant. 136, 190, 266-268 In ATH reactions, formic acid is oxidized to carbon dioxide and is
more easily removed from solution than acetone, essentially making the reaction irreversible.
Using formic acid and trialkylamine as the stoichiometric reductant and DMF as cosolvent,
we investigated the effect of catalyst loading, identity of the amine, acid:amine ratio and acid:ketone
ratio on the enantioselectivity of reduction of epoxide diketone 86.1.20 Reaction conditions
produced the keto alcohol in 83:17 to 90:10 er (table 4). The catalyst loading, identity of the amine,
acid:amine and acid:ketone ratio had relatively modest effects on er.

110

Table 4
Entry
1

Catalyst Acid:amine
Amine
Loading
Ratio
0.04
7:1
NEt(iPr)2

17:83

Acid:ketone
ratio
5:1

er

2

0.08

“

“

10:90

5:1

3

0.1

“

“

10:90

5:1

4

0.16

“

“

10:90

5:1

5

0.1

“

NEt3

10:90

5:1

6

0.12

“

“

10:90

5:1

7

0.2

“

“

10:90

5:1

8

0.1

“

“

17:83

10:1

9

0.02

5:2

NEt(iPr)2

14:86

3.2:1

10

0.04

“

“

14:86

3.2:1

11

0.1

“

“

14:86

3.2:1

12

0.1

“

“

20:80

2.5:1

13

0.1

“

NEt3

13:87

3.2:1

14

0.1

“

“

15:85

2.5:1

Interestingly, the major enantiomer observed from the reduction with formic acid was
opposite that observed when the reduction occurred in i-PrOH. The absolute configuration of
monoreduced epoxide 86.2 was confirmed to be the desired enantiomer by comparison to the
product obtained from Ogasawara’s enzymatic route.
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3.4.3 Investigating the Reversal of Enantioselectivity.
As stated above, we observed er of 19:81 for i-PrOH mediated reaction and the opposite
enantiomer with er of 82:18 for triethylammonium formate (0.2 M) in acetonitrile (Scheme 87).196
Although solvents have been shown to affect the enantioselectivity of ATH reactions,269 to our
knowledge, a reversal of enantioselectivity due to solvent has not been reported.

The generally accepted Noyori ATH mechanism, transfer of hydrogen occurs in the outercoordination sphere of the metal and is reliant of hydrogen bonding for initiation.161, 181, 186, 190, 197, 267,
270

As discussed previously, the origin of enantioselectivity is the subject of some dispute. Factors

include: sterics, solvent effects, electrostatic effects, and dispersion forces.174, 187 For aryl ketones
and ynones, a CH-π interaction between catalyst and substrate has been identified as a major
contributing factor to asymmetric induction.270 However, there have been no models explicitly
proposed for enones or dialkyl ketones. Usually when an ATH catalyst reduces acetophenone
enantioselectively, it will reduce cyclohexylmethylketone with the opposite sense of
enantioinduction, albeit in more modest optical purity.159 The general explanation is that a
favorable CH/π interaction stabilizes the transition state of the reduction of aryl ketones, while the
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reduction of dialkyl ketones is controlled solely by sterics.158 Since the mechanism of ATH of dialkyl
ketones has not been investigated in any great detail, and judging from what is known about the
ATH mechanism of aryl ketones, it is not unreasonable to believe that there might be more factors
at play in the transition state than just sterics.
It has been shown computationally that hydrogen bonding of the ketone oxygen to an
explicit solvent molecule, water192 or methanol,174 lowers the energy of the transistion state
relative to unsolvated transition states.
We hypothesize that the reversal of the sense of enantioselectivity is probably a result of
either solvent polarity or hydrogen bonding. The dielectric constants (19.9 for isopropanol and
37.5 for acetonitrile) and the concentration of hydrogen bond donors (13.3 M for neat isopropanol
and 0.2 M for formic acid/triethylamine in acetonitrile), could significantly differentiate the
respective transition states. The epoxide oxygen could also act as a hydrogen bond acceptor, which
could also play a role in differentiating the transition states. The last proposal is supported by the
observation that ATH of meso-diketone 88.1 provided the known keto alcohol 88.2 with the same
sense of enantioinduction for both sets of conditions (Scheme 88).

We wanted to probe the solvent effects on the ATH of meso-diketone 89.1 further, so we
screened the reaction against a variety of protic and aprotic solvents across a range of dielectric
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constants (Scheme 89, Table 5). Our suspicions that solvent was playing a critical role were
confirmed by entries 1 and 2 which showed the same sense of enantioinduction for reduction with
i-PrOH and formate when acetonitrile is used as cosolvent (Entries 1 and 2). This was further
supported by the unsurprising entry 12, which showed the same sense of enantioinduction for
reduction in i-PrOH even when formate was present. No clear trend between dielectric constant
and sense of enantioinduction emerged and this suggests that hydrogen bonding, probably
involving the epoxide oxygen, is most likely the central factor in the enantioinductive switch. A
general trend (with the exception of formamide [entry 3]) showed that higher concentrations of
hydrogen bond donors tended to favor the R-enantiomer (entries 7-9,12). Another interesting
finding was that the aromatic solvents benzene and toluene (entries 10 and 11) were also selective
for reduction to the R-enantiomer.

Table 5
entry

solvent

% conv.

1
Acetonitrile
4
a
2
Acetonitrile
0.2
3
Formamide
3.1
4
NEt3
7.9
5
DMSO:H2O 1:1
0.8
6
MeOH
3.9
7
EtOH
4.8
8
Benzene
3.9
9
Toluene
1.4
10
i-PrOH
5.1
ai-PrOH (1.6 eq.) was used as reductant.

er

dielectric
constant

H bond donor
concentration

18.0:82:0
28.3:71.7
30.9:69.1
33.3:66.7
44.6:55.4
57.3:42.7
68.2:31.8
77.0:23.0
78.4:21.6
86.3:13.7

37.5
37.5
111
2.42
46.0:80.1
32.7
24.5
2.27
2.38
19.9

0.2 M
0.16 M
25 M
0.2 M
35 M
25 M
17 M
0.2 M
0.2 M
13 M
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3.3.6.6 Scaling Up
We scaled up our optimized conditions for the reduction of meso-diketone 90.1 with
formate to 10 mmol in order to conduct a solvent screen, which identified acetonitrile as the
optimal cosolvent for the reduction (Scheme 90, Table 6)(entries 1-5). We also discovered that
changing the formic acid:ketone ratio from 3:1 to 1:1 led to significant increase in er (entries 3 and
6). Upon increasing the scale beyond 10 mmol, a steady deterioration in enantioselectivity was
observed (entries 6-9). We also noticed failure of the reduction to proceed to completion when the
reaction was scaled up to 120 mmol (entry 9).

Table 6
entry

solvent

acid:ketonea

Scale (mmol)

conc (M)

er

1

None

3:1

10

“

80:20

2
3
4

DMF
MeCN
THF

“
“
“

“
“
“

0.5
“
“

80:20
82:18
70:30

5

CH2Cl2

“

“

“

70:30

6
7
8

MeCN
“
“

1:1
“
“

“
30
60

0.15
“
“

90:10
82:18
79:21

“

77:23

9
“
“
120b
aMolar ratio. bReaction did not proceed to completion.

In the interest of pushing larger scale reductions to completion, we investigated increasing
the ratio of formate relative to ketone (Table 7). When formate was increased to 1.2 equivalents
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relative to epoxide 91.1, not only did the reaction proceed to completion, there was also a
significant increase in enantioselectivity from 77:23 er to 84:16 er. Once we determined that a
scaled down version of the reduction would behave analogously (entry 2), we screened various
ratios of reductant to ketone to see if we could improve the enanatioselectivity of the reduction.
Eventually, we were able to achieve 93:7 er using 1.7 equivalents of formate (entry 7).

Table 7
entry
scale (mmol)
ketone:acid ratio
1
120b
1:1
2
120
1:1.2
3
60
1:1.2
4
60
1:1.4
5
60
1:1.5
6
60
1:1.6
7
60
1:1.7
8
60
1:1.8
9
60
1:2.0
areaction did not proceed to completion.

er
77:23
84:16
84:16
89:11
91:9
92:8
93:7
87:13
87:13

Chiral stationary phase (CSP) gas chromatography (GC) determined that the intrinsic
enantioselectivity of the reduction under optimized conditions, analyzed by chiral GC at 4%
conversion, proved to be relatively modest (82:18 er). However, this is comparable to other dialkyl
ketone transfer hydrogenations.151, 265
The fact that the initial er of 82:18 improved to 93:7 by the time that the reaction is worked
up, suggested that kinetic resolution was occurring. As expected, extending the reaction time of the
reduction resulted in material with significantly improved er (99.6:0.4 at 48 h) (Table 6) as a
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consequence of kinetic resolution of the minor enantiomer. The major drawback is that isolated
yield dropped to 44%.

Table 6
entry
1
2
3
4
5

acid:ketone
ratio
1.3
1.5
1.6
1.7
1.9

3h

22 h

26 h

48 h

72 h

81.2:18.8
79.2:21.8
82.0:18.0
82.0:18.0
91.1:18.9

87.9:12.1
87.9:12.1
89.9:10.1
84.7:15.3
87.1:12.9

89.9:10.1
90.0:10.0
92.7:7.3
86.8:13.2
89.3:10.7

93.1:6.9
93.4:6.6
99.6:0.4
97.5:2.5
92.8:7.2

94.4:5.6
95.0:5.0
99.6:0.4
99.4:0.6
94.4:5.6

After much effort, we were eventually able to develop an ATH approach that mimics the
racemic route and delivers enantiopure epoxyquinol 93.4 in four steps and 16% yield from pbenzoquinone (Scheme 93)
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3.3.6.7 Synthesis of the Enantiopure C34-C25 Fragment

With a scalable synthesis of enantiopure epoxyquinol 94.1 in hand, we proceeded to
advance the synthesis of the fragment. The next step was hydrolysis of epoxyquinol 94.1 to antianti-trihydroxycyclohexenone 94.2, which was protected as bis-silyl ether 94.3 (Scheme 94).
Alkene reduction gave cyclohexanone 94.4 which was propynylated to give diol 94.5 as one
diastereomer. The secondary alcohol was protected as the carbonate to give propargyl alcohol 94.6
which was subsequently converted to O-benzylglycolic ester 94.7. Partial reduction of the alkyne
to a Z-alkene furnished Ireland-Claisen rearrangement precursor 94.8.
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Treatment of allylic ester 95.1 with LDA in the presence of TMSCl, followed by addition of
acetic acid gave Ireland-Claisen rearrangement product 95.3 in good yield. Acid 95.4 was then
converted to Weinreb amide 95.5.

Since it is known that amides can serve as good directing groups for homogenous
hydrogenation,271-274 we wanted to see if we could exploit the amide functionality of 96.1 to set the
C-29 stereocenter (Scheme 96). We believed that the existing stereocenters on the pentenoic chain
would orient the amide to the desired face of the hydrogenation in the transition state 96.2. With a
5 mol% loading of Crabtree’s catalyst in methylene chloride under 100 psi of H2, the reaction gave a
single product in excellent yield. The presence of trans-diaxial coupling between H-29 and H-34
supported our hypothesis and confirmed the conﬁguration at C29. Reducing the C28-C29 bond at
this point solves several problems encountered during the racemic synthesis which featured
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reduction with Crabtree’s catalyst as the final step. It avoids the formation of a byproduct that was
impossible to separate without further functional group transformations, it avoids unnecessary
deprotection/reprotection sequences, and it solves the problems of low yield and high catalyst
loadings.19 Also, the remaining alkene after ADR can be retained to make rigidified analogs.

3.4.6 Towards the Completion of Antascomicin B

A synthetic strategy has been developed by our lab to complete the synthesis of the C21-C34
fragment and to complete antascomicin B. The next step will be homologation of the lithio anion of
iodide 97.2 to Weinreb amide 97.1 to give 97.3 (Scheme 97).
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Next, enone 98.1 will be converted to E-hydrazone 98.2. When treated with modified
Kabalka conditions, reduction of α,β-unsaturated-E-hydrazone 98.2 should occur from the less
hindered face to produce 1,2-anti-hydrazine 98.3 followed by ADR to afford 1,4-syn-alkene 98.4 as
in the racemic synthesis (Scheme 98).18, 19, 243

Next, treatment with palladium on carbon should reduce the alkene and cleave the benzyl
and para-methoxybenzyl protecting groups, furnishing primary alcohol 99.2 (Scheme 99).275
Selective Grieco-Sharpless olefination of primary alcohol 99.2 will install the terminal alkene which
will complete the synthesis of the C21-C34 fragment of antascomicin B 99.3.
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The C34-C21 fragment 100.1 and the C20-C1 fragment 100.2 of antascomicin B will be
brought together by Yamaguchi lactonization to form triene 100.3 (Scheme 100).276 Ring closing
metathesis277 will close the macrocycle leaving universal deprotection as the last steps in the total
synthesis of the natural product antascomicin B.
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Experimental Section:

General: Standard extractive workup: the reaction mixture is poured into DI water and extracted 3
times with solvent.

Diketone 74.1. A 1000 mL round bottom, two or three necked flask, equipped with a thermometer
was charged with CH2Cl2 (400 mL) and p-benzoquinone (100 g, 0.93 mol) and cooled to -10 oC in a
MeOH/ice bath. Freshly cracked cyclopentadiene (Note 1) (30.5 g, 0.46 mol) was added over a
period of 30 min. A second 30.5 g portion of cyclopentadiene was added in a similar fashion (Note
2). The mixture was then stirred in the ice bath for 1 h and then allowed to warm to rt over 30 min.
The solvent was removed in vacuo and the crude material was purified by recrystallization from
hexanes. The pale-yellow crystals were washed with cold hexanes, air dried, and then dried
completely under high vacuum to give diketone 74.1 as pale-yellow crystals (100.4 g, .577 mol,
62%). Data matched that previously reported.278

Note 1: To prepare cyclopentadiene, dicyclopentadiene was placed in a single necked RBF with a
stirring bar. The flask was then equipped with a vigreux column which was attached to a condenser
with recirculating ice water. The flask was then heated to 220 oC. The point of condensation was
monitored by thermometer to make sure that the collection did not occur above 42 oC which is the
point at which dicyclopentadiene distills. The cracked cyclopentadiene was collected at -78 oC.
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Note 2: The cyclopentadiene was added in two portions to mitigate the dimerization that occurs
upon warming to rt.

Diol 74.2. A suspension of diketone 74.1 (3 g, 17.2 mmol) and CeCl3-7H2O (9.61 g, 25.8 mmol) in
methanol (100 mL) was cooled to -10 oC in MeOH/ice bath. NaBH4 (0.65g, 17.2 mmol) was then
added at such a rate that the reaction mixture did not rise significantly above 0 oC. Crude product
was extracted with CH2Cl2, dried with MgSO4, dried in vacuo, and recrystallized from acetone to give
diol 74.2 as white crystals (2.45 g, 13.76 mmol, 80%) data matched that previously reported.29

Monoacetate 74.3. A suspension of diol 74.2 (18.3 g, 102.7 mmol), vinyl acetate (56.78 mL, 616.1
mmol), and Amano lipase PS-D (18.3 g) in THF (400 mL) and NEt3 (40 mL) was stirred at rt for four
days. The reaction mixture was filtered through a Celite pad with Et2O and solvent was removed in
vacuo. The crude material was purified by column chromatography over silica gel with 20/80 ethyl
acetate/hexane to give monoacetate 74.3 as colorless crystals (18.54 g, 84.2 mmol, 82%). Data
matched that previously reported. 29
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Silylacetate 75.2. Monoacetate 75.1 (16.0 g, 72.7 mmol) was added to a solution of imidazole
(13.30 g, 195.5 mmol), TBSCl (14.30 g, 94.8 mmol), and DMAP (0.87 g, 6.3 mmol) in DMF (500 mL).
The reaction mixture was allowed to stir at rt for 4.5 h then quenched with water, extracted with
Et2O, dried over MgSO4, and concentrated in vacuo. The crude material was purified by column
chromatography over silica gel with 10/90 ethyl acetate/hexane to give silylacetate 75.2 as
colorless oil (21.1 g, 63.2 mmol, 87%). Data matched that previously reported.29

Silyl Alcohol 75.3. Silylacetate 75.2 (20.5 g, 61.3 mmol) was added to a solution of K2CO3 (16.95 g,
122.6 mmol) in MeOH (300 mL) and H2O (60 mL). The reaction mixture was allowed to stir at rt for
6 h. The crude product was extracted in Et2O, dried over MgSO4, concentrated in vacuo, and
purified by column chromatography over silica gel with 10/90 ethyl acetate/hexane to give silyl
alcohol 75.3 as colorless oil (16.14 g, 55.17 mmol, 90%). Data matched that previously reported.29
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Silyl Ketone 75.4. Silyl alcohol 75.3 (17.9 g, 61.1 mmol) was added to a solution of PDC (45.97 g,
122.2 mmol) in dichloromethane (100 mL) and allowed to stir at rt for 4 h. Reaction mixture was
filtered over Celite with CH2Cl2 and concentrated in vacuo. The crude material was purified by
column chromatography over silica gel with 20/80 ethyl acetate/hexane to give silyl ether 75.4 as a
colorless oil (14.38 g, 49.5 mmol, 81%). Data matched that previously reported.29

Epoxide 75.5. Silyl ketone 75.4 (14.78 g, 50.5 mmol) was added to a solution of t-Bu
Hydroperoxide (34.73 mL, 254.2 mmol) and Triton B (35.47 mL, 51.0 mmol) in benzene (200 mL).
The solution was heated under reflux for 2h. Reaction mixture was extracted with Et2O, dried over
MgSO4, and concentrated in vacuo. Crude material was purified by column chromatography over
silica gel with 10/90 ethyl acetate/hexane to afford epoxide 75.5 as yellow oil (10.9 g, 35.5 mmol,
70%). Data matched that previously reported.29
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Enone 75.6. Epoxide 75.5 (4.08 g, 13.31 mmol) was dissolved in 100 mL of diphenyl ether. The
reaction mixture was heated to 190 oC until completion as monitored by TLC, and then allowed to
cool to rt. The solvent was removed from the mixture by column chromatography over silica gel
with hexane. The product epoxide enone 75.6 was isolated as a white crystal by column
chromatography over silica gel with 10/90 ethyl acetate/hexane (1.92 g, 7.99 mmol). Data
matched that previously reported.29

Catalyst Precursor. A mixture of [{RuCl2(η6-p-cymene)}2] or [{RuCl2(η6-mesitylene)}2] (306.2 mg,
.5 mmol), (S,S)-TsDPEN (366.3 mg, 1 mmol), and triethylamine in 2-propanol was added to a round
bottom flask and heated under nitrogen to 80o C for 1 h. After completion as monitored by TLC, the
reaction mixture was concentrated by rotary evaporation and the resultant solids were collected by
filtration and washed with water. The orange crystals were then dried under reduced pressure
(509 mg, 0.8 mmol) data matched that previously reported.157
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Ru-TsDPEN. (180 mg, .276 mmol) of the catalyst precursor was added to a round bottom flask
with KOH (.23 g, .41 mmol) and CH2Cl2 (4mL) and allowed to stir for five minutes. After five
minutes, H2O (4mL) was added and allowed to stir for 5 minutes. Alternatively Ru-TsDPEN was
prepared by dissolving [{RuCl2(η6-p-cymene)}2] or [{RuCl2(η6-mesitylene)}2] (306.2 mg, .5 mmol)
and (S,S)-TsDPEN (366.3 mg, 1 mmol) in CH2Cl2 (5 mL) and allowing to stir for 5 minutes. KOH (83
mg,1.5 mmol)and water (5 mL) is then added and the mixture is allowed to stir for an additional 5
minutes. Reaction is complete when the color turns from deep rust orange to dark purple.
Reaction was extracted in CH2Cl2, dried over CaH2, and then concentrated in vacuo to give RuTsDPEN 31.2 as dark purple crystals (quant. yield). Data matched that previously reported.157

Epoxide 93.2. Diels-Alder adduct 74.1 (36.08g, 207 mmol) was dissolved in THF (450 mL) at rt.
35% H2O2 in H2O (40.22 mL, 414 mmol) was slowly added over 15 min. Following addition of
peroxide, saturated aqueos NaHCO3 (45 mL, cat.) was added. Reaction was allowed to proceed for
2h at rt and then extracted with ether, dried over MgSO4, concentrated in vacuo, and purified by
recrystallization from EtOH. Product was isolated as white flaky crystals (29.52, 155.3 mmol, 75%)
Data matched that reported.
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Monoreduced epoxide 93.3. Epoxide diketone 93.2 (190 mg, 1 mmol) was dissolved in a solution
of i-PrOH and (S, S)-RuTsDPEN and allowed to stir until disappearance of starting material by TLC.
Rotary evaporation of the crude reaction mixture followed by separation via column
chromatography over silica gel and a 20/80 Ethyl Acetate/Hexane mixture afforded the epoxide 3
in variable yields. Alternatively, Ru(p-cymene)(S,S-TsDPEN) (0.25 g, 0.39 mmol, 0.65 mol %) and
then epoxydiketone 93.2 (11.4 g, 60 mmol) were added to a solution of formic acid (3.85 mL, 102
mmol), triethylamine (14.3 mL, 102 mmol) and acetonitrile (500 mL) at -10 °C. The reaction
mixture was allowed to slowly warm to rt and stirred for ca. 16 h. The mixture was concentrated in
vacuo and then stirred for ca. 16 h in 30/70 ethyl acetate/hexanes (300 mL) with activated
charcoal (10 g). The mixture was filtered through a plug of Celite with 30/70 ethyl acetate/hexanes
and concentrated in vacuo. At this point, the residue could be purified by flash chromatography
(20/80 ethyl acetate/hexanes) followed by recrystallization in diethyl ether to give monoreduced
epoxide 93.3 as colorless crystals (9.8 g, 51 mmol, 85%, er 93:7). For reduction product with
higher enantiopurity, repeat the steps for reduction by formic acid and let stir for ca. 48h or until
the minor enantiomer is present in insignificant quantities as measured by chiral (β-dex) GC (er
99.6:0.4). The product can be recrystallized to enantiopurity with diethyl ether as colorless crystals
(5.10 g, 44%). M.P. 71-73 oC; [α]23D = -0.71 (c 0.56 CH2Cl2); IR (film) 3472, 3059, 2989, 1712 cm-1;
1HNMR

(400 MHz, CDCl3) δ 1.19 (d, J = 9.54 Hz, 1H), 1.30 (d, J = 8.38 Hz, 1H), 1.45 (dt, J = 8.39 Hz,

1.88 Hz, 1H), 2.97 (ddd, J = 11.20, 5.75, 3.21, 1H), 3.03 (br s, 1H), 3.09 (br s, 1H), 3.17 (dd J = 11.0
Hz, 3.43 Hz, 1H), 3.57 (m, 1H), 3.29 (d, J = 4.36, 1H), 4.65 (ddd, J = 9.35 Hz, 5.73 Hz, 3.39 Hz, 1H),
6.22 (ddd, J = 3.05 Hz, 5.53 Hz, 16.55 Hz, 2H); 13CNMR (400 MHz, CDCl3) δ 42.60, 44.88, 45.06,
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49.58, 51.28, 54.70, 59.54, 67.18, 135.46, 135.67, 208.1. Anal Calcd for C11H12O3: C, 68.74; H, 6.29.
Found: C, 68.75; H, 6.31.

Epoxyquinol 4. A solution of epoxide 93.4 (10 g, 52.03 mmol) in diphenyl ether (250 mL) was
stirred at rt while nitrogen was bubbled through for 30 minutes. The reaction mixture was then
heated to 210 oC (still bubbling through with nitrogen) until decomposition product became a
significant spot as monitored by TLC. After cooling to room temperature, the reaction mixture was
poured onto a column of silica gel using hexane to elute off solvent. When all solvent was eluted,
the reaction mixture was eluted with 20/80 ethyl acetate/hexane. A second silica gel column 1/99
-10/90 MeOH/CH2Cl2 1% gradient followed by recrystallization with diethyl ether yielded pure
epoxyquinol 93.4 (5.25 g, 41.62 mmol, 80%) as white powdery crystals. M.P. 84-86 oC; [α]23D = 1.92 (c 0.46 CH2Cl2); IR (film) 3395, 2993, 1695 cm-1; 1HNMR (400 MHz, CDCl3) δ 2.13 (d, J = 8.71,
1H), 3.50 (ddd, 3.50 Hz, 1.81 Hz, 1.12 Hz, 1H), 3.81 (ddd, J = 3.69 Hz, 2.58 Hz, 1.22 Hz, 1H), 4.72,
(dddd, J = 8.37 Hz, 4.61 Hz, 2.26 Hz, 1.11 Hz, 1H), 6.03, (ddd, J = 10.53 Hz, 1.71 Hz, 1.31 Hz, 1H), 6.70
(ddd, J = 10.53 Hz, 4.67 Hz, 2.57 Hz, 1H); 13CNMR (400 MHz, CDCl3) δ 53.31, 57.73, 63.02, 127.12,
144.01, 193.63. Anal Calcd for C6H6O3: C, 57.14; H, 4.80. Found: C, 57.07; H, 4.91.
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Trihydroxycyclohexenone 94.2. Epoxyquinol 93.4 (10 g, 79.30 mmol) was distributed in 1 gram
aliquots to 10 parallel synthesizer tubes and a solution with DI H2O (20 mL) was made in each tube
and they were heated to 90 oC for 4 days. H2O was then co-evaporated with MeCN and the brown
residue was adsorbed on silica gel. The silica gel/residue was added to a silica gel column using
CH2Cl2. Mixture was eluted with 0/99-10/90 MeOH/CH2Cl2 at 1% gradient. The second fraction
was collected and recrystallized in EtOH to give trihydroxycyclohexanone 94.2 (5.71 g, 39.65 mmol,
50%) as colorless crystals. M.P. 136-138 oC; [α]23D -0.885 (c 0.437 1:1 MeOH:CH2Cl2); IR (film)
3400, 2835, 1693 1H NMR (400 MHz, CD3OD) δ 3.58 (dd, J = 10.87 Hz, 8.28 Hz, 1H), 4.03 Hz (d, J =
10.88 Hz, 1H), 4.36 (m, 1H), 6.04 (dd, J = 10.33 Hz, 2.56 Hz, 1H), 6.92 (d, J = 10.33 Hz, 1.94 Hz, 1H);
13CNMR

(400 MHz, CH3OD) δ 70.12, 75.17, 76.99, 124.57, 150.36, 197.21. Anal Calcd for C6H8O3: C,

50.00; H, 5.59. Found: C, 49.89; H, 5.65.

Enone 94.3. A solution of TBSCl (16.67 g, 111 mmol) and imidazole (9.67 g, 142 mmol) in dry DMF
(25 mL) was added to trihydroxycyclohexenone 94.2 (4.55 g, 32 mmol) in dry DMF (25 ml). After
stirring at room temperature for 4 h, the reaction mixture was quenched with ice water, extracted
with ether, dried over MgSO4, and concentrated in vacuo. The crude product was purified by flash
column chromatography on silica gel using 5/95 ethyl acetate/hexane, followed by recrystallization
with cold hexane to give enone 94.3 (5.88 g, 16 mmol, 50%) as white crystals. M.P. 101-103oC;
[α]23D = -0.11 (c 0.24 CH2Cl2); IR (film) 3394, 1647 cm-1; 1HNMR (400 MHz, CDCl3) δ 0.11 (s, 3H),
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0.19 (s, 6H), 0.24 (s, 3H), 0.94 (s, 9H), 0.96 (s, 9H), 2.56 (d, J = 1.72 Hz, 1H), 3.77 (m, 1H), 4.03 (d, J =
10.55 Hz, 1H), 4.46 (dt, J = 7.96 Hz, 2.16 Hz, 1H), 5.98 (dd, J = 10.36 Hz, 2.41 Hz, 1H), 6.70 (dd, J =
10.36 Hz, 1.91 Hz, 1H);

13CNMR

(400 MHz, CDCl3) δ -5.40, -4.91, -4.46, -4.13, 18.15, 18.61, 25.76,

25.94, 72.68, 78.55, 78.70, 126.86, 150.71, 196.78. Anal Calcd for C18H36O4Si2: C, 58.02; H, 9.74.
Found: C, 58.15; H, 9.93.

Hydroxy ketone 94.4. A mixture of enone 94.5 (5.28 g, 14.17 mmol) and 10% Pd/C (0.950 g, 0.90
mmol Pd) in dry methanol (100 ml) was stirred under an H2 atmosphere (1 atm) for 7 h. Following
completion of the reaction by TLC, the reaction mixture was filtered through celite and
concentrated. The crude product was purified by flash column chromatography on silica gel using
1/99-3/97 gradient of ethyl acetate/hexane, followed by recrystallization with cold hexane to give
hydroxyl ketone 94.4 (4.67 g, 12.47 mmol, 88%) as white crystals. M.P. 76-78 oC; [α]23D = +0.084 (c
0.26 CH2Cl2); IR (film) 3414, 1736 cm-1; 1HNMR (400 MHz, CDCl3) δ 0.06 (s, 3H), 0.14 (s, 3H), 0.16
(s, 3H), 0.17 (s, 3H), 0.92 (s, 9H), 0.94 (s, 9H), 1.60 (m, 1H), 2.04 (m, 1H), 2.37 (m, 2H), 2.53 (d, J =
2.53 Hz, 1H), 3.47 (td J = 9.96, 1.54, 1H), 3.87 (ddd, J = 11.21, 8.67, 4.69, 1H), 4.07 (d, J = 9.77 Hz,
1H);

13CNMR

(400 MHz, CDCl3) δ -5.33, -4.49, -4.44, 18.10, 18.59, 25.78, 25.84, 29.65, 34.67, 35.72,

72.84, 79.71, 205.66. Anal Calcd for C18H38O4Si2: C, 57.70; H, 10.22. Found: C, 58.39; H, 10.55.
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Diol 94.5. Propynyl magnesium bromide (70.7 ml, 0.5 M in THF, 35.32 mmol) was added dropwise
to a solution of hydroxyl ketone 94.4 (4.41 g, 11.77 mmol) in THF (200 ml) at -10oC. After warming
to room temperature over 5 h, the reaction mixture was quenched with cold NH4Cl (aq) solution,
extracted with ether, dried over MgSO4, and concentrated in vacuo. The crude product was purified
by flash column chromatography on silica gel using 3/97-5/95 ethyl acetate/hexane gradient to
give diol 94.5 (3.86 g, 9.30 mmol, 79%) as white crystals. M.P. 50-52oC; [α]23D = +0.031 (c 0.26
CH2Cl2); IR (film) 3540, 2113 cm-1; 1HNMR (400 MHz, CDCl3) δ 0.11 (s, 3H), 0.12 (s, 3H), 0.14 (s,
3H), 0.17 (s, 3H), 0.91 (s, 9H), 0.95 (s, 9H), 1.49 (td, J = 13.48 Hz, 3.85 Hz, 1H), 1.71 (dddd, J = 17.06
Hz, 14.18 Hz, 10.91 Hz, 3.58 Hz, 2H), 1.86 (s, 3H), 1.91 (dt, J = 12.97 Hz, 3.38 Hz, 1H), 2.21 (s, 1H),
2.56 (s, 1H), 3.29 (d, J = 9.25 Hz, 1H), 3.42 (m, 2H);

13CNMR

(400 MHz, CDCl3) δ -4.70, -4.53, -4.24, -

3.83, 3.62, 18.10, 18.43, 25.86, 26.02, 29.38, 33.23, 72.65, 74.50, 77.71, 79.36, 80.27, 82.41; Anal
Calcd for C21H42O4Si2: C, 60.82; H, 10.21. Found: C, 60.81; H, 10.35.

Propargyl alcohol 94.6. n-BuLi (2.35 mL, 2.8 M in Hexanes, 6.58 mmol) was added dropwise to a
solution of diol 94.5 (2.55 g, 6.15 mmol) in ether (100 ml) at -78oC. After 30 min, Di-tert-butyldicarbonate (1.75 g, 7.99 mmol) was added dropwise and the reaction mixture was allowed to
slowly warm to room temperature over 7 h. Following completion of the reaction as monitored by
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TLC, reaction mixture was quenched with cold NH4Cl (aq) solution, extracted with ether, dried over
MgSO4, and concentrated in vacuo. The crude product was purified by filtration through a silica gel
plug using 10/90 ethyl acetate/hexane, followed by recrystallization with cold hexane to give
propargyl alcohol 94.6 (2.55 g, 6.09 mmol, 99%) as white crystals. M.P. 126-128 oC; ; [α]23D =
+0.080 (c 0.196 CH2Cl2); IR (film) 3580, 1752 cm-1; 1HNMR (400 MHz, CDCl3) δ 0.07 (s, 3H), 0.08 (s,
3H), 0.11 (s, 3H), 0.12 (s, 3H), 0.88 (s, 9H), 0.92 (s, 9H), 1.49 (s, 9H), 1.78 (m, 2H), 1.88 (s, 3H), 1.92
(t, J = 3.55 Hz, 1H), 2.40 (s, 1H), 3.40 (d, J = 9.64 Hz, 1H), 3.56 (td, J = 9.80 Hz, 5.85 Hz, 1H), 4.71 (t, J
= 9.34 Hz, 1H).

13CNMR

(400 MHz, CDCl3) δ -4.73, -4.48, -4.47, -4.20, 3.68, 17.94, 18.16, 25.80,

25.87, 28.01, 29.76, 33.20, 72.41, 72.96, 78.29, 78.62, 80.99, 81.61, 83.35, 152.98; Anal Calcd for
C26H50O6Si2: C, 60.66; H, 9.79. Found: C, 60.92; H, 10.03.

Alkyne 94.7. n-BuLi (1.48 ml, 2.8 M in Hexanes, 4.14 mmol) was added dropwise to a solution of
propargyl alcohol 94.6 (1.42 g, 2.76 mmol) in ether (35 ml) at -78oC. After 20 min, the acid chloride
(1.27 g, 6.90 mmol) was added dropwise and the reaction mixture was allowed to slowly warm to
room temperature over 9 h. When the reaction ceased as observed by TLC, reaction mixture was
quenched with cold NH4Cl (aq) solution, extracted with ether, dried over MgSO4, and concentrated
in vacuo. The crude product was purified by flash column chromatography on silica gel using 1/993/97 ethyl acetate/hexane gradient giving alkyne 94.7 (1.21 g, 1.82 mmol, 66%, 97% brsm) as a
colorless oil. [α]23D = +0.314 (c 1.42, CH2Cl2); IR (film) 2266, 1747 cm-1; 1HNMR (400 MHz, CDCl3) δ
0.04 (s, 3H), 0.07 (s, 3H), 0.07 (s, 3H), 0.07 (s, 3H), 0.87 (s, 9H), 0.88 (s, 9H), 1.39 (m, 1H), 1.49 (s,
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9H), 1.80 (m, 2H), 1.92 (s, 3H), 2.83 (dt, J = 13.08 Hz, 3.55 Hz, 1H) 3.55 (td, J = 9.18 Hz, 7.48 Hz, 1H),
3.64 (d, J = 9.44 Hz, 1H), 4.04 (d, J = 2.45 Hz, 2H), 4.63 (q, J = 11.52 Hz, 11.53 Hz 2H), 4.76 (t, J = 9.33
Hz, 1H), 7.34 (m, 5H);

13CNMR

( 400 MHz, CDCl3) δ-4.75, -4.56, -4.49, -4.14, 3.90, 17.94, 18.17,

25.73, 25.79, 28.01, 29.28, 30.22, 67.36, 71.86, 73.34, 73.99, 76.41, 80.74, 80.97, 81.84, 86.35,
128.02, 128.20, 128.46, 136.97, 152.83, 186.28; Anal Calcd for C35H58O8Si2: C, 63.40; H, 8.82. Found:
C, 61.16; H, 8.66.

Allylic ester 94.8. A mixture of the alkyne 94.7 (2.1 g, 3.167 mmol), pyridine (0.128 ml, 1.58
mmol), and 5% Pd/BaSO4 (1.35 g, 0.633 mmol) dissolved in ethyl acetate (25 ml) was shaken in a
Parr bottle under an H2 atmosphere (100 psi) for 6 h. The reaction mixture was filtered through
celite and concentrated. The crude product was purified by flash column chromatography on silica
gel using 0/100-5/95 ethyl acetate/hexane gradient to give allylic ester 94.8 (1.74 g, 2.62 mmol,
83%, 94% brsm) as a colorless oil. [α]23D = -0.278 (c 0.88 CH2Cl2); IR (film) 1751 cm-1; 1HNMR
(400 MHz, CDCl3) δ 0.03 (s, 3), 0.07 (s, 3H), 0.07 (s, 3H), 0.09 (s, 3H), 0.85 (s, 9H), 0.87 (s, 9H), 1.31
(m, 1H), 1.48 (s, 9H), 1.55 (m, 1H), 1.82 (d, J = 6.72 Hz, 3H), 1.91 (m, 1H), 2.75 (dt, J = 13.16 Hz, 3.43
Hz, 1H), 3.64 (ddd, J = 11.05 Hz, 9.02 Hz, 5.04 Hz, 1H), 4.02 (d, J = 2.13 Hz, 2H), 4.08 (d, J = 9.50 Hz,
1H), 4.57 (t, J = 4.56 Hz, 1H), 4.63 (m, 2H), 5.78 (m, 2H), 7.32 (m, 5H);

13CNMR

(400 MHz, CDCl3) δ -

4.66, -4.58, -4.36, -4.21, 15.18, 17.93, 18.15, 25.80, 25.95, 28.01, 28.18, 29.35, 30.95, 67.56, 71.95a,
73.26, 75.66, 77.24, 80.37, 81.81, 86.76, 124.26, 127.96, 128.06, 131.11, 137.14, 153.05, 168.90;
Anal calcd for C35H60O8Si2: C, 63.64; H, 9.34. Found: C, 63.75; H, 9.18.
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Pentenoic acid 95.3. n-BuLi (1.07 ml, 2.8 M in Hexanes, 3.01 mmol) was added dropwise to a
solution of diisopropylamine (0.423 ml, 3.01 mmol) in THF (20 ml) at -78oC. After 20 min, this
solution was cannulated to a solution of allylic ester 94.8 (1.00 g, 1.50 mmol) and TMSCl (0.57 ml,
4.51 mmol) in THF (20 ml) at -78oC. After 10 min AcOH (0.103 ml, 1.80 mmol) was added and the
reaction mixture was allowed to slowly warm to rt. After 3 h, the reaction mixture was quenched
with cold saturated NH4Cl (aq) solution, extracted with ether, dried over MgSO4, and concentrated
in vacuo. The crude product was then dissolved in ether (5 ml), treated with NEt3 (0.30 ml, 2.15
mmol), and purified by flash chromatography over silica gel eluting with 1% NEt3 in ether, then 1%
HCO2H in ether. Removal of excess formic acid in vacuo gave pentenoic acid 95.3 (0.78 g, 1.17
mmol, 78%, 99% brsm) as a colorless oil. [α]23D = +0.424 (c 1.32 CH2Cl2); IR (film) 3414, 1750,
1651 cm-1; 1HNMR (400 MHz, CDCl3) δ -0.01 (s, 3H), 0.04 (s, 3H), 0.05 (s, 3H), 0.08 (s, 3H), 0.85 (s,
9H), 0.90 (s, 9H), 1.05 (d, J = 6.81 Hz, 3H), 1.29 (m, 1H), 1.47 (s, 9H), 1.56 (m, 1H), 1.86 (m, 1H), 2.50
(d, J = 13.63 Hz, 1H), 2.98 (m, 1H), 3.65 (ddd, J = 11.28 Hz, 8.89 Hz, 5.14 Hz, 1H), 3.85 (dd, J = 6.41,
3.08, 2H), 4.38 (t, J = 9.16 Hz, 1H), 4.47 (d, J = 11.50 Hz, 1H), 4.73 (d, J = 11.50 Hz, 1H), 5.61 (d, J =
10.49 Hz, 1H), 7.34 (m, 5H). 13CNMR (400 MHz, CDCl3) δ -4.96, -4.90, -4.86, -4.39, 8.50, 17.89, 18.19,
23.31, 25.773, 25.929, 28.01, 33.78, 35.40, 72.54, 72.93, 73.95, 81.16, 83.34, 83.96, 123.74, 127.69,
127.99, 128.33, 136.96, 137.60, 153.12, 175.83. Anal calcd for C35H60O8Si2: C, 63.21; H, 9.09. Found:
C, 61.29; H, 9.52.
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Weinreb Amide 96.2. Freshly distilled MsCl (0.090 ml, 1.16 mmol) was added dropwise to a
solution of pentenoic acid 96.1 (0.70 g, 1.05 mmol) and triethylamine (0.439 ml, 3.15 mmol) in THF
(30 ml) at 0oC. After 30 min, HN(OMe)Me (0.096 ml, 1.58 mmol) was added dropwise and the
reaction mixture was allowed to warm to rt over 6 hours. The reaction mixture was quenched with
saturated NH4Cl (aq) solution, extracted with ether, dried over MgSO4, and concentrated in vacuo.
The crude product was purified by filtration through a silica gel plug with 1% NEt3 in ether.
Starting material was recovered with 1% formic acid in ether. After removal of solvents under
vacuum, Weinreb amide 96.2 was isolated (0.55 g, .776 mmol, 73.9%) as clear oil. [α]23D = +0.234
(c 0.74 CH2Cl2); IR (film) 1633, 1732 cm-1; 1HNMR (400 MHz, CDCl3) δ -0.02 (s, 3H), 0.00 (s, 3H),
0.03 (s, 3H), 0.08 (s, 3H), 0.83 (s, 9H), 0.91 (s, 12H), 1.25 (m, 1H), 1.48 (s, 9H), 1.54 (td, J = 14.25 Hz,
13.93 Hz, 2.91 Hz, 1H), 1.76 (m, 1H), 2.62 (d, J =13.39 Hz, 1H), 2.99 (m, 1H), 3.21 (s, 3H), 3.54 (s,
3H), 3.63 (ddd, J = 11.31, 8.88, 5.13 Hz, 1H), 3.87 (dd, J = 9.41, 1.63 Hz, 1H), 4.13 (d, J =8.20 Hz, 1H),
4.40 (d, J =11.80 Hz, 1H), 4.47 (t, J = 9.10 Hz, 1H), 4.59 (d, J = 11.79 Hz, 1H), 5.48 (d, J = 10.22 Hz,
1H), 7.26 (m, 5H);

13CNMR

(MHz, CDCl3) δ -4.90, -4.85, -4.83, -4.40, 14.10, 17.86, 18.24, 22.65,

23.46, 25.77, 25.94, 28.02, 31.55, 33.61, 35.31, 61.17, 71.93, 72.55, 73.97, 81.02, 83.89, 125.17,
127.66, 127.93, 128.37, 137.21, 137.65, 152.99, 173.19. Anal Calcd for C37H65NO8Si2: C, 62.76; H,
9.25; N, 1.98. Found: C, 62.08; H, 9.24; N, 1.93.
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Reduced amide 97.3. A mixture of Weinreb amide 96.2 (0.40 g, 0.565 mmol) and Crabtree’s
catalyst (0.023 g, 0.0282 mmol) in CH2Cl2 (100 mL) was shaken in a Parr bottle under H2 (100 psi)
overnight. The reaction mixture was concentrated in vacuo and purified by flash column
chromatography on silica gel using 20/80 ethyl acetate/hexane to afford reduced amide 97.3 (0.39
g, 0.55 mmol, 97%) as a colorless oil. [α]23D = +0.076 (c 1.32 CH2Cl2); IR (film) 1675, 1748 cm1; 1HNMR

(400 MHz, CDCl3) δ 0.02 (s, 3H), 0.03 (s, 3H), 0.04 (s, 3H), 0.08 (s, 3H), 0.72 (q, J = 13.81

Hz, 1H), 0.86 (s, 9H), 0.88 (s, 9H), 0.89 (s, 3H), 1.23 (m, 3H), 1.48 (s, 9H), 1.72 (m, 2H), 1.88 (dd, J =
13.73 Hz, 3.15 Hz, 1H), 2.06 (m, 2H), 3.10 (t, J = 9.5 Hz, 1H), 3.19 (s, 3H), 3.47 (ddd, J = 11.27 Hz,
9.25 Hz, 4.92 Hz, 1H), 3.58 (s, 3H), 4.12 (d, 6.70 Hz, 1H), 4.36 (d, J = 11.22 Hz, 1H), 4.45 (d, J = 9.06
Hz, 1H), 4.54 (d, J = 11.22 Hz, 1H), 7.30 (m, 5H); 13CNMR (MHz, CDCl3) δ -4.60, -4.46, -3.90, -3.56,
17.94, 18.02, 18.10, 25.69, 25.84, 26.14, 28.08, 32.26, 32.98, 33.57, 39.14, 41.8, 61.08, 71.92, 72.93,
76.35, 81.22, 81.40, 83.69, 127.79, 128.19, 128.35, 137.52, 153.21, 173.18; Anal Calcd for
C37H67NO8Si2: C, 62.58; H, 9.51; N, 1.97. Found: C, 62.78; H, 9.60; N, 1.92.
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